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ABSTRACT
To investigate the potential of chemotherapeutants to control the oyster pathogen
Perkinsus marinus, anticoccidial and antifungal compounds were tested in vitro on infected
hemolymph and cultured P. marinus cells and in vivo on infected oysters. In addition,
acute toxicity to oysters was determined for six anticoccidials.
In vitro experiments with infected hemolymph consisted of 24 h exposure of 0.2
mL hemolymph aliquots to concentrations ranging from 100 mg/L to 0.01 mg/L of
amphotericin-B, amprolium, arprinocid, cycloheximide, lasalocid, malachite green,
monensin, sulfadimethoxine, and a potentiated sulfadimethoxine, followed by incubation in
fluid thioglycollate medium (FTM) to determine prezoosporangia abundance. Lasalocid,
malachite green, and amphotericin-B were the most effective compounds reducing
prezoosporangia abundance, relative to the untreated control group, at concentrations as
low as 10 mg/L. Cycloheximide, monensin, and to a lesser extent sulfadimethoxine, were
also effective but only at the highest concentration tested (100 mg/L). At concentrations
lower than 10 mg/L, none of the compounds tested had a significant effect on abundance of
prezoosporangia.
In vitro experiments with cultured P. marinus consisted of 24 h exposure of 10^
cells to 100 mg/L, 10 mg/L, and 1 mg/L of amphotericin-B, and 100 mg/L of cimetidine,
cycloheximide, fumagillin, 5-fluorocytosine, ketoconazole, lasalocid, and monensin,
followed either by incubation in FTM to determine abundance and size of prezoosporangia,
or by addition of Neutral Red to determine cell viability. Amphotericin-B, lasalocid, and
monensin were effective in reducing prezoosporangia abundance, size, and/or cell viability.
No effects of cycloheximide on cultured cells were apparent
Lasalocid, monensin, and malachite green, were toxic to oysters at concentrations
below 10 mg/L. The 96-hr. LC50 for lasalocid was 0.59 mg/L. No median lethal dose was
determined for monensin or malachite green, but oyster mortality resulted from exposures
ranging from 1 mg/L to 10 mg/L of either compound.
In three in vivo experiments, infected oysters were exposed to amprolium,
arprinocid, cycloheximide, lasalocid, monensin, malachite green, potentiated
sulfadimethoxine, and sulfadimethoxine at various concentrations. Only cycloheximide was
effective in reducing P. marinus infections. After 15 days of exposure to 10 mg/L of
cycloheximide, weighted prevalence significantly declined from 3.78 in untreated controls
to 2.10 in treated oysters. In addition, infections as measured by repeated hemolymph
samples from individual oysters, significantly decreased after treatment Extension of

cycloheximide exposure to 30 days similarly reduced P. marinus prevalence and weighted
prevalence. Infections, however, were not completely eliminated even after 30 days of
exposure to 10 mg/L of cycloheximide. Furthermore, infections progressed after treatment
was discontinued as indicated by an increase in weighted prevalence from 0.71 at the end
of treatment to 1.31 one month later.
In summary, cycloheximide baths of at least 10 mg/L renewed every other day for 2
weeks were necessary to reduce P. marinus infections in oysters held at 20 °C and 20 p p t
Continuation of the treatment schedule for 2 additional weeks did not result in eradication
of parasites, and infections relapsed once treatment stopped.

IN VITRO AND IN VIVO EFFECTS OF CHEMOTHERAPEUTANTS ON THE
OYSTER PARASITE, PERKINSUS MARINUS

INTRODUCTION

The oyster industry in Virginia experienced serious decline since an MSX epizootic
caused large scale mortality to oysters in the lower portion of the Chesapeake Bay in 1960
(Burreson 1991a, Haskin & Andrews 1988, Hargis & Haven 1988). Between 1960 and
1985 Haplosporidium nelsoni, the causative agent of MSX disease, was responsible for
most of the disease induced mortality in Chesapeake Bay oysters. Since 1985, however,
Perkinsus marinus has gradually replaced H. nelsoni as the most important pathogen in
Chesapeake Bay. Estimates of up to 50% total annual oyster mortality have been attributed
to P. marinus disease (Andrews, 1988a). Although over harvesting and water quality
deterioration have contributed to the decline of the oyster resource and industry (Hargis &
Haven 1988), disease mortality and decreased investment in private farming, because of the
fear of losses to disease, are believed to be primarily responsible for much of the decline in
oyster landings (Burreson, 1991a).
Sublethal effects of P. marinus on oyster growth and reproduction have also been
proposed as additional factors impacting production. Ray et al. (1953) reported an average
of 33% reduction in condition index of heavily infected oysters compared to uninfected
oysters. Andrews (1961), and Menzel and Hopkins (1955) found that P. marinus infection
reduces oyster shell growth. Similarly, Paynter and Burreson (1991) correlated shell
growth reduction and oyster condition reduction with the acquisition and progression of P.
marinus infections. Mackin (1962) reported that infections disrupted gonadal tissue and
impaired gonad development Decrease in oyster setting as a result of lethal and sublethal
effects of disease on broodstock has been proposed as an additional factor contributing to
the decline of oyster populations (Haven & Fritz 1985, Ford & Figueras 1988).
Perkinsus marinus is endemic in most of the lower Chesapeake Bay including the
lower sections of all rivers in Virginia. The parasite also now occurs in the upper parts of

the rivers, but abundance is low and little disease mortality occurs there. Perkinsus
marinus has thrived in densely planted private beds, but it has persisted even in sparsely
populated public beds. It is not clear how oyster density affects disease transmission, but
denser beds seem to have had the highest mortality (Andrews 1988a). Infections follow a
seasonal pattern of maximum prevalence and intensity during summer and fall and
minimum prevalence and intensity during winter and spring. Temperature and salinity
modulate the seasonal pattern of infections and play a major role in determining the
distribution and abundance of the parasite. At temperatures above 20 °C and salinities
above 12 ppt P. marinus develops rapidly and can be lethal to oysters within a month. In
natural beds most oysters die after two consecutive summers of exposure (Andrews,
1988a). In response to above normal seasonal temperature and salinity regimes such as the
persistent droughts in 1985-1988, P. marinus increased its distribution and abundance
(Burreson and Andrews 1988). Below normal seasonal salinities, such as the ones
registered in 1989 and 1990 due to abnormally high rainfall, however, did not eradicate the
pathogen (Burreson 1991b). Therefore, for P. marinus disease to disappear, below
average temperature and salinity conditions may need to persist for a very long time.
The taxonomy of this parasite is still controversial. Initially, P. marinus was placed
in the fungal genus Dermocystidium on the basis of the characteristic eccentric nucleus and
vacuole with refringent vacuoplast observed in hematoxylin and eosin stained sections of
infected oyster tissue (Mackin et al. 1950). Later, it was transferred to the fungal genus
Labyrinthomyxa by Mackin and Ray (1966). More recently, electron microscopic
observations of the apical complex of zoospores by Perkins (1976a) led Levine (1978) to
create the class Perkinsea and the genus Perkinsus within the protozoan phylum
Apicomplexa to accommodate P. marinus. Although this latter classification has been
endorsed by the Society of Protozoologists (Levine 1980), the taxonomic status of P.
marinus and indeed of the phylum Apicomplexa, has not been settled. Since 1980, there
have been 3 independent revisions of the phylum Apicomplexa, reviewed by Canning

(1986), which propose to re-establish Sporozoa as the phylum name. Two revisions, by
Krylov & Kostenko (1981) and Corliss (1984), propose to include P. marinus within the
sporozoans under a new class or order. The third proposal, by Vivier (1982), disregards
the similarities of the apical complex in P. marinus with that of other sporozoans, and
suggests placing the species within the flagellates based on the lack of a sexual phase in its
life cycle. Recent biochemical studies of Perkinsus sp. indicate that the genus is
phylogenetically closer to dinoflagellates and to coccidian and piroplasm apicomplexans
than to fungi or flagellates (Goggin & Barker 1993).
In oysters, P. marinus can be detected by direct microscopic examination of tissue
or hemolymph smears (Mackin, 1962). Those methods, however, are not suitable for
routine diagnosis given the difficulty in observing a parasite of such a small size. The
smallest meronts found in oyster tissue are 2-4 |im in diameter (Perkins, 1988).
Histological sectioning and staining with hematoxylin and eosin can also be used for
diagnosis but these are time consuming methods (Johnson and Sparrow, 1961). A rapid
diagnostic method currently used is the thioglycollate culture method developed by Ray
(1952). Ray's method consists of incubating whole animal tissues or pieces of infected
oyster tissues in fluid thioglycollate medium (FTM). This procedure results in enlargement
of P. marinus meronts (called prezoosporangia or hypnospores after enlargement) to sizes
that are easily observed by light microscopy, especially after staining with iodine. The
oyster tissues that are usually examined ate mantle, gill, and rectum. Extensive use of the
thioglycollate culture method by oyster biologists since the 1950s has shown that P.
marinus is an important agent of oyster mortality along the east and gulf coasts of the
United States (Ray 1954, Mackin 1962, Andrews 1976). For assessment of P. marinus
infection intensity, Ray (1954) and later Mackin (1962), developed ordinal scales which
rate the relative abundance and distribution of the parasite in pieces of oyster tissue. More
quantitative methods based on counting the number of prezoosporangia per unit area and
including the use of replicates were developed by Scott et al. (1985). The number of

prezoosporangia per unit weight after extraction from oyster tissue has also been used as a
measure of infection intensity (Choi et al., 1989). More recently, a hemolymph assay has
been developed for diagnosis. The "hemolymph technique", which is based on incubation
of hemolymph in FTM, has the advantage of allowing for repeated diagnosis of the same
individual without having to sacrifice the oyster (Gauthier and Fisher, 1990).
Despite recent developments that allow culture of the parasite continuously in vitro
(La Peyre et al. 1993), the life cycle of P. marinus is still not well understood. The known
life stages of P. marinus in oysters are: meronts (2-4 |im coccoid uninucleate cells), mature
meronts (10-20 iim cells containing an eccentrically situated vacuole), and schizonts
typically containing 8-32 merozoites (Perkins, 1988). These life stages have been
extensively observed and described from live smears and oyster tissue sections using light
(Mackin et al. 1950, Mackin 1951, Mackin and Wray 1952, Mackin 1962) and electron
microscopy (Perkins 1966,1969,1976a, 1988). Based on those observations, the
following sequence of events has been postulated. Immature meronts, also called
merozoites, develop into meronts which then form multicellular schizonts by successive
bipartitioning or progressive cleavage of the protoplasm. Subsequent rupture of the
schizont releases immature meronts (Perkins 1976a, 1988). The rest of the life cycle,
especially what happens outside the oyster is unclear.
It should be noted that incubation in FTM results in 15 |im to greater than 100 |xm
enlarged cells called prezoosporangia or hypnospores, but these cells do not multiply and
do not survive in FTM for more than 10 days (Perkins 1966,1988, Perkins and Menzel
1966). Transfer of prezoosporangia into seawater, however, results in production and
release of biflagellated zoospores from zoosporangia (Perkins 1966, Perkins and Menzel
1966).
Perkinsus marinus zoospores have been shown to infect oyster tissue in laboratory
experiments. Only light infections resulted even when tissues were exposed to millions of
zoospores (Perkins, 1988). In contrast, heavy infections have easily been obtained by

exposing live oysters to tissue minces from infected oysters (Ray 1952, Mackin 1962).
This suggests that meronts and not zoospores may be the primary infective cell type
(Perkins, 1988).
Infections can be initiated in the gill, mantle, or gut epithelia, or in connective tissue
near the basement membrane (Perkins, 1976b). Most initial infections have been observed
in the digestive epithelium from the stomach to the rectum (Mackin, 1951). Early stages of
infection are believed to occur in the hemolymph (Gauthier and Fisher, 1990). In fact,
immature meronts have often been found within oyster hemocytes (Perkins, 1988).
Parasites may grow and multiply within hemocytes or in the intercellular spaces of the
hepatopancreas and gut (Mackin 1962, Perkins 1976b). Since oysters have an open
circulatory system, it has been hypothesized that hemocytes phagocytize the pathogens and
convey them all over the body (Mackin 1962, Andrews 1988a).
Advanced infections are characterized by abscesses of the epithelia, massive
concentration of parasites throughout the connective tissue, and occlusion of hemolymph
sinuses by parasites and hemocytes as well (Mackin 1951, Perkins 1976b). Rapid
multiplication of the parasites results in destruction of hemocytes and tissues and usually
causes death in about 1 month at 25-30 °C (Mackin 1962, Andrews 1988a).
Perkinsus marinus can be transmitted directly from oyster to oyster. Experimental
infection in the laboratory is usually carried out by adding a few infected oysters to an
aquarium where a group of about 25 uninfected oysters are maintained ("proximity
method"), by adding minced tissue from infected oysters to the aquarium ("feeding
method"), or by injecting a suspension of parasites in seawater into the mantle cavity of
individual oysters ("injection method"). Comparison of these methods indicates that
injection produces mortality in the shortest time (90% mortality in a group of 25 oysters in
6 weeks) and also ensures simultaneous infections in the group. Injection, however, has
the disadvantage of introducing another stress to the oysters. By the feeding method, 90%
mortality occurs in about 9 weeks, but the additional stress is eliminated (Ray, 1954). The

proximity method is seldom used since it is more time consuming.
The effect of dosage of P. marinus infective cells on oyster mortality was studied
by Mackin (1962) using the injection method. His work indicated that oysters (N = 25)
receiving a single 1.0 mL injection containing 5 x 10^- 5 x 10^ parasite cells per oyster
start to die after 3 weeks at a rate of 2% per day. Oysters injected with 5 x 1()3 cells start to
die after 4 weeks at a rate of 0.3-1.0% per day, and oysters injected with less than 100 cells
were not affected after 6 weeks when the experiment was terminated.
Andrews and Hewatt (1957) investigated the effects of low temperature on the
establishment and progression of infections. Oysters injected with P. marinus extracted
from infected tissues did not develop infections when maintained at temperatures lower
than 15 °C for six weeks while oysters initially maintained at 28 °C for one week and
subsequendy transferred to 15 °C conditions developed only light infections during the
same period. Oysters held continuously at 28 °C for six weeks experienced 90% mortality.
Perkinsus marinus has proven to be extremely difficult to eradicate once it has
invaded an area and no treatment for individual oysters is available. Low temperature and
salinity have been shown to arrest infections, but not in a manner that could be applicable
for treatment (Andrews 1988b). Unlike Haplosporidium nelsoni, which can be eliminated
by a 2 week exposure to salinities of 10 ppt or less (Ford 1985), P. marinus persisted after
8 weeks of exposure to salinities as low as 6 ppt (Ragone & Burreson 1993).
Control measures that could possibly prevent or reduce the impact of disease on
oyster populations in Virginia include management strategies and breeding programs to
increase oyster survival after exposure to disease agents. Andrews and Ray (1988)
proposed management strategies for private oyster beds based on isolation of beds,
harvesting early and cleaning beds, and closely monitoring disease. Implementation of
such proposals, however, seems to be constrained by the potential risk of transmission of
infections from contiguous public areas.
Breeding programs to increase oyster survival involve selecting surviving oysters

from disease endemic areas and breeding them over successive generations. Such an
approach has been used successfully to increase survival of oysters exposed to H. nelsoni
over eight generations of selection (Ford and Haskin 1987). Improvement in survival of
oysters challenged with H. nelsoni, however, has not been correlated to particular cellular
or humoral defense mechanisms of disease resistance (Ford 1986), but appears to result
from an overall physiological superiority that makes cultured oysters more tolerant to the
effects of disease (Myhre 1973). Stocks selected for increased survival when subjected to
H. nelsoni challenge, however, have not attained increased survival when challenged with
P. marinus suggesting that the physiological requirements of the two pathogens are
different (Burreson, 1991a). A continuing effort to develop oysters with increased survival
to P. marinus using native strains is underway at VIMS but it is unlikely that substantial
progress can be made within a few years.
Another strategy to circumvent disease affecting oysters in the Chesapeake Bay
would be to introduce another oyster species more resistant and/or tolerant to diseases than
C. virginica. The proposed introduction of C. gigas has been considered by Mann et al.
(1991). Arguments that support the proposed introduction of C. gigas are based on results
from laboratory challenges with P. marinus that showed a lower prevalence and intensity of
infections and lower oyster mortality in C. gigas than in C. virginica (Meyers et al. 1991).
Proposals to introduce C. gigas in the Chesapeake Bay, however, are controversial due to
potential parallel introduction of foreign disease agents and/or displacement of local biota,
including extant C. virginica populations, by C. gigas. Nevertheless, carefully controlled
introduction of C. gigas for research is possible and has recently been effected in Virginia
for challenge studies with H. nelsoni and P. marinus following the proposal of Mann et al.
(1991).
Chemotherapy, the focus of this study, is another approach that could be used to
control P. marinus infections in oysters. Applications of this approach would include
treatment of seed and broodstock oysters as well as oysters held in trays or aquaria for use

in aquaculture and research. To date, there have been only two studies that explored the
effects of chemotherapeutants on P. marinus. At a time when the parasite was classified as
a fungus, Ray (1966a) examined the effects of 12 antifungal antibiotics on P. marinusinfected oyster tissue. Initially, antifungal agents were directly added to FTM containing
pieces of infected tissues. Compounds that markedly inhibited P. marinus enlargement at
concentrations of 50 mg/L or less were further tested by adding them to autoclaved sea
water aliquots containing infected oyster tissues. At weekly intervals, pieces of gill tissue
were checked for ciliary activity and then tissues were rinsed in sterile seawater and
transferred for incubation in FTM. Among the 12 compounds tested, only cycloheximide
and to a lesser extent streptimidone, which is structurally related to cycloheximide, were
effective when added to FTM or seawater cultures at concentrations ranging from 10 to 50
mg/L.
The results presented above prompted Ray (1966b) to expose P. marinus-infected
oysters to cycloheximide baths in seawater of 25 ppt and 25 °C. In a first experiment,
oysters were exposed to 1- 50 mg/L cycloheximide baths renewed weekly for periods of 45
to 164 days. In a second experiment, oysters were exposed to a 10 mg/L cycloheximide
bath for 30 days (renewed weekly). In the first experiment, prevalence (collectively for all
treated oysters), declined from 70% before treatment to 50% after treatment. In the second
experiment, weighted prevalence declined from 3.00 before treatment to 1.25 after
treatment. In both experiments, survival was greater for treated oysters than for untreated
oysters. In the first experiment, there was 100% survival of treated oysters and only 20%
survival of untreated oysters after 90 days of treatment. In the second experiment, there
was 93% survival of treated oysters and 70% survival of untreated oysters after 28 days of
treatment A trend of increased survival with increasing concentrations and longer
exposure time was reported. Furthermore, the intensity of the infections appeared to be
lower as treatment time increased. Treatment appeared to arrest mortalities associated with
moderate-heavy infections. In addition, infection intensities seemed to be reduced during

treatment, although they may have later relapsed. Conclusions were limited because
sample sizes were small (N = 5 in most cases), and no statistical analysis was performed
on the data.
Other studies on the effects of chemicals on P. marinus include Scott et al. (1985)
who found that exposure of infected oysters to a combination of low salinity and
chlorine-produced oxidants (CPO) significantly decreased P. marinus related mortalities as
compared to untreated controls held at low salinities. In vitro studies by Goggin et al.
(1990) indicate that Perkinsus spp. prezoosporangia free of host tissue die within 30
minutes when exposed to chlorine solutions of 6 ppm or higher.
Since the work of Ray in 1966, there have been several developments that allowed
for re-examination of the effects of chemotherapeutants on the oyster pathogen P. marinus.
The referred developments include ultra structural studies of P. marinus leading to the
present classification of the parasite within the Apicomplexa, extension of the thioglycollate
method to diagnose P. marinus-'mfected hemolymph, and the recent formulation of a
medium that supports P. marinus cultures, as previously mentioned. In addition,
anticoccidials of wide use against avian coccidiosis have more recently been recommended
for use in fish (Meyer & Schnick 1989).
Criteria to select chemotherapeutants for the present investigation included prior
information concerning efficacy against P. marinus, efficacy against parasites
taxonomically related to P. marinus, use on and toxicity to aquatic organisms and food
animal species, water solubility, mode of chemical action, availability and cost Similar
criteria have been used before to select chemicals for investigations on control of parasitic
diseases (Griffin 1989). It was very difficult to identify compounds that met all or most of
the aforementioned criteria, but there was at least one reason to include each compound
chosen.
Very little information could be found on the use of antifungals and anticoccidials in
marine organisms. Disease control research in freshwater aquaculture has been conducted
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for several decades but advances in understanding and control of disease in marine
aquaculture is recent, largely within the last 20 years. Reports on chemotherapy of marine
organisms are mostly restricted to bacterial diseases affecting finfish, crustaceans, and
larval stages of bivalves (Sindermann & Lightner 1988). Moreover, treatments for internal
infections in aquatic organisms, including freshwater ones, are not well established (Meyer
& Schnick 1989). Therefore, background information for the present study was mostly
limited to freshwater or terrestrial organisms.
Considering the new classification of P. marinus within the Apicomplexa, and the
fact that chemotherapeutants have been widely developed against coccidian parasites in
poultry, the following anticoccidial compounds were selected. Amprolium, arprinocid, and
sulfadimethoxine were selected because they are fairly safe anticoccidial agents.
Sulfadimethoxine has also been used in fish as antibacterial agent The latter compounds
have been without adverse effects even when administered at several times their therapeutic
dose in poultry or fish (McDougald 1982, Maestrone et al. 1984). The water solubility of
sulfonamide compounds, which include sulfadimethoxine, has made them more useful for
treatment of established infections than other less water soluble compounds. The mode of
action of sulfadimethoxine, amprolium, and arprinocid is by competitive inhibition of
metabolites leading to the formation of vitamins and nucleic acids. Sulfadimethoxine is an
antagonist of para-aminobenzoic acid (PABA) which is involved in the formation of amino
acids. Amprolium is a partially water soluble analog of the vitamin thiamine, and
arprinocid blocks formation of nucleic acids (McDougald 1982, Gutteridge and Coombs
1977). Chemical structures of anticoccidial and antifungal compounds used in this study
are given in Appendix A.
Unlike the anticoccidial agents described above, the polyether ionosphores lasalocid
and monensin are not water soluble and have a narrow margin of safety. In embryonic
chick kidney cell cultures inoculated with Eimeria tenella sporozoites, monensin was toxic
to kidney cells at concentrations ranging from 100 mg/L to less than 1 mg/L and was active
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against E tenella sporozoites at concentrations lower than 0.1 mg/L (Strout & Ouellettte
1973). The LD 50 for monensin ranges from 2 mg/kg in horses to 185 mg/kg in chickens
(McDougald 1982). Despite their narrow margin of safety and their mediocre performance
in laboratory tests, polyether antibiotics including lasalocid and monensin, have shown
results superior to other compounds when tested under field conditions. Efficacy and
toxicity of polyether ionosphorus antibiotics is related to their ability to disrupt the selective
permeability of membranes (McDougald 1982,1990).
Toltrazuril, a synthetic anticoccidial compound developed in Europe, has also
shown considerable activity against coccidians. microsporidians, and myxozoan parasites
of fish and insects (Melhom et al. 1988, Schmahl et al. 1989). Toltrazuril, however, could
not be used in the present study because it is not available in the U.S. market.
Based on Ray's (1966 a,b) success with cycloheximide, it as well as the other
antifungal agents were selected. Cycloheximide and malachite green were included even
though they are potentially harmful to human health or non-target organisms (Bower 1989,
Meyer & Schnick 1989). They have been successfully used against various aquatic
pathogens and therefore constitute good reference standards. In addition to the use against
P. marinus, cycloheximide has been used to control Labyrinthuloides haliotidis, a pathogen
of juvenile abalone (Bower, 1989). Bower found that exposure of infected abalone to 1
mg/L of cycloheximide for 5 consecutive days reduced infection prevalence and abalone
mortality. No lethal effects on abalone survival were reported after a 10 day exposure to
100 mg/L of cycloheximide.
In vitro exposure of yeasts, fungal pathogens of man, and bacteria to cycloheximide
by Whiffen (1948) showed that cycloheximide is highly active against certain yeasts and
fungal pathogens. Among the yeasts and fungal pathogens exposed to cycloheximide by
Whiffen, Cryptococcus neoformans, Nematospora phaseoli, Pichia membranaefasciens,
several species of Saccharomyces and other yeasts species were inhibited by concentrations
of less than 1 mg/L. None of the tested bacteria were inhibited when exposed to
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cycloheximide concentrations as high as 1000 mg/L. Median lethal dose of cycloheximide
by intravenous injection ranged from 2.7 mg/kg in rats to 150 mg/kg in mice (Whiffen
1948).
Malachite green was included because it has been the most extensively used external
parasiticide of aquatic organisms (Meyer & Schnick, 1989). It is an aryl-methane dye with
wide antimicrobial activity against bacteria, fungi, and protozoa. Aryl-methane dyes are
particularly active against Gram-negative bacteria, and also against oomycete fungi
responsible for saprolegniasis in freshwater fish and other fungal infections in marine
Crustacea (Alderman 1985). The use of malachite green as an internal chemotherapeutant,
however, has not been widely investigated. Exposure of rainbow trout to 1.5 mg/L of
malachite green for 1 day prevented the development of proliferative kidney disease (PKD)
Clifton-Hadly & Alderman (1987). Acute toxicity of malachite green to freshwater
invertebrates, as reported by Bills et al. (1977), varies from 0.51 mg/L -122 mg/L.
Malachite green is a respiratory enzyme poison known to destroy mitochondria (Alderman
1985). In addition to its destructive action against mitochondria, malachite green is known
to be teratogenic in laboratory animals, and its use in aquaculture in the US has therefore
not been approved by FDA (Meyer & Schnick 1989).
Despite the fact that malachite green is known to cause adverse effects, it is still
used as a reference standard against which new antifungal agents are compared. In an
effort to find a substitute for malachite green to treat saprolegnial fungi infecting fish,
Bailey and Jeffrey (1989) tested cycloheximide, amphotericin-B, ketoconazole, 5fluorocytosine, as well as 200 or more other antifungal agents on two species of
Saprolegnia ,in vitro, and on infections in rainbow trout eggs. Minimum inhibitory
concentrations and toxicity to eggs were determined in short term exposures (< 1 h r ).
Cycloheximide showed moderate antifungal activity in vitro but was toxic to eggs at
exposures of 25 mg/L. In vitro exposures to > 1000 mg/L of amphotericin-B or 300 mg/L
of ketoconazole had low antifungal activity. Toxic effects of amphotericin-B and
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ketoconazole, however, were not reported. In Bailey and Jeffrey's paper, 5-Fluorocytosine
was referred to as being either ineffective, toxic to non-target organisms, or otherwise
unsuitable for further testing. No further details were given, however, to ascertain the
specific reason for removing 5-Fluorocytosine from further testing. Exposure of infected
eggs to S mg/L of malachite green was effective without causing acute mortality to eggs.
Amphotericin-B has been effective in treatment of systemic mycosis in humans and
domestic animals. Grayson (1982) reported that amphotericin-B was active in vitro against
pathogenic yeasts at concentrations of 0.01-2.0 mg/L. Its activity against opportunistic,
subcutaneous and dermatophytic fungi was less, 3.12-30 mg/L. The mode of action of
amphotericin-B is by preferentially binding to sterol components in the membranes of
fungi. The LD50 in laboratory animals ranges from 4-6 mg/kg by intravenous
administration to > 8000 mg/kg by oral administration. Systemic mycosis caused by fungi
of the genera Aspergillus, Blastomyces, Candida, Cryptococcus, and Histoplasma can be
controlled by amphotericin-B (Deacon 1984). Similar to amphotericin-B, ketoconazole
interferes with membrane function in fungi by blocking the synthesis of ergosterol. The
LD 50 of ketoconazole ranges from 210 mg/kg in rats to > 900 mg/kg in dogs by oral
administration (Janssen 1989). 5-fluorocytosine has been used against yeast infections
caused by Candida albicans and Cryptococcus neoformans, but it has little effect against
other mycotic fungi. Its mode of action is by interfering with RNA and protein synthesis in
fungi. It is almost completely non-toxic to mammals (Deacon 1984, Merck & Co. 1986).
Two other compounds were selected for in vitro testing. Fumagillin has shown
significant activity on preventing development of Pleistophora sp., a microsporidian
parasite of eels (Kano et al. 1982). Cimetidine inhibits gastric acid secretion and is used as
an anti-ulcerative (Merck & Co. 1989). It should be noted that arprinocid, lasalocid,
monensin, and potentiated sulfadimethoxine are almost insoluble in water. Therefore, the
use of a solvent is necessary. Dimethyl sulfoxide (DMSO) has been used successfully to
dissolve anticoccidial agents, and, provided that its final concentration was less than 1.0%,
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it did not interfere with parasite development or host cell integrity (Ryley and Wilson,
1976). Furthermore, toxicity tests on several species of fish showed that more than 3% of
DMSO is required to produce mortality in a 96h test (Willford, 1968).
Methods to search for chemotherapeutants in animals have largely relied on
empirical testing. Theoretical models that relate the structure of a chemical to its biological
activity have been developed, but their role in drug discovery has been minimal.
Therefore, in vitro and in vivo tests are still the preferred methods for detection of
antiparasitic activity (Lichtfield 1958, Schnitzer and Hawking 1963, Ryley and Wilson
1976, Grayson 1982). The objective of in vitro and in vivo is to detect antiparasitic activity
of compounds at levels non toxic to the host. In the long term, effective compounds are
expected to produce no side effects on the host and to be purged or removed prior to
harvest when the animal is used for human consumption.
Based on Ray's results with antibiotic antifungal agents and considering the new
classification of P. marinus within the Apicomplexa I hypothesized that antifungal and/or
anticoccidial compounds would be acdve against P. marinus and could possibly be used to
control established infections in oysters. It was reasonable to expect that anticoccidial
compounds would be effective in controlling P. marinus infections, since P. marinus has
recendy been classified within the phylum Apicomplexa, which contains coccidians (Levine
1978). Given that several anticoccidial agents have already been approved by the Federal
Drug Administration (FDA) for use in poultry, their registration for use in aquaculture
would be facilitated (Meyer & Schnick, 1989).
The experimental approach of the present investigation was to test chemicals against
P. marinus-Mected hemolymph and cultured P. marinus cells (in vitro experiments), and
against infections in oysters (in vivo experiments). Since there very little information was
found on recommended doses of anticoccidial agents for treatment of aquatic organisms
(particularly bivalves), the in vivo studies included a toxicity experiment to determine
possible lethal concentrations to oysters. Perldnsus cell cultures and most antifungal agents

only became available towards the end of the investigation. Therefore, initial experiments
focused on anticoccidial agents and testing in vitro was accomplished on infected
hemolymph whereas later experiments focused on antifungal agents using P. marinus
cultures preferentially for later in vitro tests.

METHODS

In vitro experiments
The first in vitro experiments consisted of adding hemolymph from P. marinusinfected oysters to chemical baths containing 100 mg/L of active ingredients of
amprolium, arprinocid, cycloheximide, lasalocid, malachite green, monensin,
sulfadimethoxine, and potentiated sulfadimethoxine for one day. If 100 mg/L baths
significantly inhibited the number of parasite cells enlarging to the prezoosporangia
(hypnospore) stage, infected hemolymph was then exposed to 10 mg/L, 1 mg/L, 0.1
mg/L, and 0.01 mg/L baths during a subsequent experiment. Amphotericin-B was tested
in a separate trial at 100 mg/L, 10 mg/L and 1 mg/L.
This methodology was based on the hemolymph technique (Gauthier & Fisher
1990), modified to test the effects of chemicals on parasite cells (Table 1). Oyster shells
were notched adjacent to the adductor muscle, using a lapidary saw. Infected hemolymph
was withdrawn with a syringe from the adductor muscle sinus of at least 10 oysters
(selected from a heavily infected group) until a 10 mL stock was obtained. After mixing
the stock by vortex, 0.2 mL aliquots were dispensed into 1.5 mL microcentrifuge tubes.
Infected hemolymph aliquots were then exposed to 1 mL chemical baths for one day at
room temperature (20°C). After exposure to chemical baths, hemolymph aliquots were
centrifuged at 265 x g for 15 minutes to concentrate parasite cells in pellets; cell free
serum was discarded. The pellets, containing merozoite, meront and schizont stages of
the parasite, were further washed once in 0.22 |im-filtered York River water (FYRW) at
23 ppt salinity and resuspended in 1 mL FTM containing 0.05 mL of penicillin and
streptomycin (2500 units/mL). The inoculated media was incubated at 25 °C in the dark
for 5-7 days, then samples were centrifuged at 265 x g for 15 minutes and the supernatant
was discarded. Pellets were resuspended in 1 mL 2 M NaOH for 15 minutes and then

washed twice in distilled water. Pellets were stained with 2 drops of Lugol’s iodine
working solution (Gauthier & Fisher 1990). After staining, the volume of each sample
was raised to 1 mL with distilled water and dispensed into separate wells of a 24-well
tissue culture plate. Enumeration of the total number of recognized prezoosporangia per
well was made on an inverted scope at 100 X magnification. Criteria to identify
prezoosporangia included size, color, and overall appearance. In general, coccoid cells
greater than 6 |im in diameter and/or mostly blue in color were recognized as
prezoosporangia.
Chemical baths containing amprolium, sulfadimethoxine, cycloheximide, or
malachite green were freshly prepared by dissolving 10 mg of the chemical in 10 mL
FYRW at 23 ppt salinity and then serially diluting to the desired concentration. When
amphotericin-B, arprinocid, lasalocid, monensin, and potentiated sulfadimethoxine were
used, 10 mg of the chemical was first added to 1 mL of dimethylsulfoxide (DMSO),
thoroughly mixed using a vortex blender, and then diluted in FYRW at 23 ppt salinity.
The experimental design consisted of triplicate treatments and included an
untreated control group, and a solvent control group tested at 1% DMSO (the highest
concentration of solvent used). Since Amphotericin-B became available at a later stage,
it was tested separately using a new set of solvent and untreated controls. Therefore,
results for Amphotericin-B on infected hemolymph are presented separately. A one-way
ANOVA was used to examine differences in mean number of cells between treatments.
When significant F-ratios were detected, a Dunnett’s test was performed to examine the
data for differences between individual treatments and controls.

Table 1. Flow chart of methods for in vitro experiments with infected hemolymph. Note:
In the hemolymph technique (Gauthier & Fisher 1990), hemolymph is withdrawn from
individual oysters to assess P. marinus infections. In the present technique, hemolymph
was pooled from several oysters (> 10) and exposed to treatment prior to incubation in
FTM to test for chemical effects.

Collect and pool 10 mL hemolymph from infected oysters

Mix and divide into 0.2 mL aliquots

Expose to 1 mL chemical baths for 1 day

Rinse in FYRW and incubate in FTM

Stain and transfer prezoosporangia to microtiter wells

Count No. prezoosporangia per well(lOOX)
Compare untreated controls to treated groups
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In addition to experiments in which hemolymph was used as a source for P.
marinus, other in vitro experiments involved testing chemicals on cultured-P. marinus
cells (Table 2). Stocks of the serologically identified Perldnsus marinus isolate;
Perkinsus-1 was supplied by Dr. J. F. La Peyre at VIMS and maintained in 35 cm^ tissue
culture flasks (Coming Glass Works, Coming NY) in 22 ppt JL-ODRP medium at 28°C
(La Peyre et al., 1993). Cell density in stock cultures was 5 x 10^ cells/mL. In all
experiments, log-phase cultures were used.
Aliquots containing approximately 10^ cells were removed from stock cultures
with a micropipette and exposed for 1 day to 1 mL chemical solutions in 1.5 mL
microcentrifuge tubes. After exposure to chemical baths, treated cells were centrifuged at
265 x g for 15 minutes to concentrate cell pellets and the supernatant was discarded.
Pellets were rinsed once in 22 ppt artificial seawater (ASW) and incubated in FTM as in
the previous experiment. ASW was prepared by dissolving seawater synthetic basal salt
mixture (Sigma Chemical Co.) in distilled water. After incubation, pellets were placed
on 24 well tissue culture plates. Prezoosporangia were counted from 3 replicate fields at
100 X in each of three replicate wells. Cell diameter was measured at 320 X on 25
haphazardly selected cells in each replicate.
In a separate assay, cells were tested for viability after exposure to chemicals.
Instead of using microcentrifuge tubes, cells were seeded directly on 24 well plates and
exposed to 1 mL chemical baths for 1 day. Then, 0.10 mL of neutral red stain (0.05%)
was added to each well. Neutral red is a vital stain. Live cells uptake the stain while dead
cells do not. After 15 minutes, stained and unstained cells were counted at 320 X using
an inverted microscope. Counts were made on 2 replicate fields in each of two wells.
The choice of using prezoosporangia abundance and size as endpoints of chemical
activity was based on the prior use of inhibition of prezoosporangia enlargement as an
indicator of anti-P. marinus activity by Ray (1966a). Other possible endpoints such as
zoospore formation could have been used on non-cultured cells but development of

zoospores in the laboratory has not been consistently achieved. Viability was selected as
an endpoint because the procedure for its determination has been well established and is
reliable, and because cytocidal effects could be expected at least from those compounds
that disrupt membrane function such as amphotericin-B, lasalocid, and monensin.
Eight chemicals (amphotericin-B, cimetidine, cycloheximide, 5-fluorocytosine,
fumagillin, ketoconazole, lasalocid, and monensin) were tested on cultured-P. marinus
cells. In addition, there was a solvent control (1% DMSO) and a 22 ppt ASW control.
All compounds were dissolved in DMSO by dissolving 10 mg of each chemical in 1 mL
DMSO and mixing with a vortex. The 22 ppt ASW was added to bring the final volume
to 10 mL. The resulting solution was diluted in ASW until the concentration of the
chemicals was 100 mg/L and the concentration of the solvent was 1% . Lasalocid and
monensin were tested at a later stage than the other compounds. Therefore, results for
lasalocid and monensin are presented separately. A list of compounds tested on infected
hemolymph (prior experiment) and on cultured cells (this experiment) is provided in
appendices B and C.

Table 2. Flow chart of methods for in vitro experiments with cultured-P. marinus cells.

Seed microtiter wells or microcentrifuge tubes with 105 cells

Expose to 1 mL chemical baths for 1 day

Stain with Neutral Red and count or Rinse and incubate in FTM

Stain and transfer prezoosporangia to microtiter wells

Count and measure prezoosporangia (100X)
Compare untreated controls to treated groups
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T o xicity experim ent
For this experiment, P. marinus-free oysters (70 mm mean shell height, 32 gm
mean whole weight) were obtained from the Wye River in Maryland in May 1991. After a
2 week acclimation to 25°C and 17 ppt in 1.0 |im FYRW, a sample of 25 oysters was taken
for diagnosis of P. marinus in a combined sample of rectal, gill, and mantle tissue taken
from each oyster following the method of Ray (1952). Subsequently, the remaining
oysters were randomly assigned to aquaria for exposure to chemical baths.
The experimental design consisted of duplicate treatments of 5 oysters per 10 L
bath. Oysters were exposed to baths of amprolium, arprinocid, lasalocid, monensin,
potentiated sulfadimethoxine, or sulfadimethoxine at four concentrations: 0.01 mg/L, 0.1
mg/L, 1 mg/L, and 10 mg/L. In addition, there were 2 control baths-one untreated control
and one solvent control at 0.1% DMSO. Each bath was renewed daily for 4 days. Stocks
of chemical solutions were freshly prepared each day by adding 100 mg of active
ingredients to 10 mL of DMSO, thoroughly mixing using a vortex blender, and adjusting to
the desired concentration by dilution in FYRW. Sulfadimethoxine, a highly water soluble
compound, was dissolved directly in FYRW.
Oysters were fed a daily radon of diatoms (Chaetoceros calcitrans and Thallasiosira
pseudonana) and/or flagellates (Isochrysis galbana) at an approximate concentration of 5 x
10® to 5 x 10^ cells/L. Chemical solutions were dispensed into aquaria, following the
addition of food. Aeration was continuously provided to aquaria. Aquaria were inspected
daily at the time of water change for dead oysters. Oysters that remained open after the
tanks were emptied for water exchange were considered dead. When appropriate, the
concentration of exposure associated with a 50% mortality at 96 hr (LC50 ) was estimated
by graphic and binomial methods (Gelber et al. 1985).
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In vivo experiments
There were 3 experiments designed to determine the effect of chemicals on P.
marinus infections in oysters. Experiment 1 was designed to determine the effect of 4 day
chemical baths on preventing infections (Table 3). Adult oysters (>50 mm shell height)
were obtained from the Wye River in Maryland, in August 1991, cleaned of fouling
organisms, and acclimated to 25“C and 20 ppt in 1 pm FYRW for one week. Then, FTM
tissue diagnosis for P. marinus was performed, as previously described, on 25 oysters.
The remaining oysters were randomly assigned to 25 L aquaria in groups of 25. Treatment
consisted of 4 day static renewal baths of 0.1 mg/L of amprolium, arprinocid, lasalocid,
monensin, potentiated sulfadimethoxine, and 10 mg/L of sulfadimethoxine. There were six
treatments (one for each chemical) and three controls (untreated unchallenged, untreated
challenged, solvent challenged) all tested in duplicate. Chemicals were prepared and added
to aquaria, as in the toxicity experiment In the present experiment however, amprolium
(which is 20% water soluble) was directly dissolved in water without previous dissolution
in DMSO. The final concentration of DMSO in exposure media was kept below 0.1%.
Following exposure to chemicals, oysters (N = 25) were challenged to daily
consecutive doses of 1 x 10? P. marinus cells per 25 L aquarium for 2 consecutive days.
To obtain parasite cells for challenge, tissues from 20 oysters (selected from a source
showing 100% prevalence), were minced in a blender with 250 mL of 0.22 FYRW and
then filtered through a 300 pm, 75 pm, 53 pm, and 20 pm sieve set. Parasite cell
abundance was estimated as follows from three 1-mL subsamples taken from the resultant
suspension. Each subsample was incubated in 10 mL FTM containing 0.5 mL of penicillin
and streptomycin at 25 °C in the dark for 1 day. After incubation, samples were
centrifuged at 265 x g for 15 minutes to discard the FTM supernatant. Pellets, containing
parasite cells, were washed twice in distilled water and resuspended in 1 mL distilled
water. Aliquots of the resulting cell suspensions were then counted using a

hemocytometer, and then the stock suspension was adjusted to yield the desired
concentration.
Oysters were fed an algae diet in aerated aquaria as in the previous experiment.
Water was maintained at acclimation conditions throughout the experiment and changed
once a day. Six weeks after challenge, all oysters were sacrificed and diagnosed for
disease as before. Prevalence was calculated by dividing the number of infected oysters by
the total number of oysters diagnosed for each treatment replicate. Infection intensity in
tissue samples was determined as described by Mackin (1962) and categorized as negative,
light, moderate, or heavy. To calculate weighted prevalence, the following code numbers
were assigned to the intensity (I) categories: 0 = negative, 1 = light, 3 = moderate, and 5 =
heavy (Paynter & Burreson 1991). Weighted prevalence was calculated as the average
value of infection intensity for number of oysters diagnosed in the treatment replicate (X
Ini/N). Where Ini = sum of prevalences for each intensity category, and N = total number
of oysters diagnosed. Differences in average prevalence and weighted prevalence between
treated and untreated groups were examined by one way ANOVAs.

Table 3.

3D U

Tissue diagnosis

Flowchart of methods for experiment 1. Number of oysters in parenthesis. Treatment groups consisted of 2 replicate aquaria
containing 23 oysters each. P.Sulfa.=Potentiated sulfadimethoxine, Sulfa.=Sulfadimethoxine.

Experiment 2 was conducted to determine if amprolium, cycloheximide, malachite
green, and/or sulfadimethoxine baths were effective in reducing P. marinus infections in
oysters (Table 4). Adult oysters (>50 mm shell height), were collected from Point of
Shoals in the James River in September 1992, cleaned of fouling organisms, individually
labeled using a water proof marker, and subsequently maintained in a static tank filled with
1.0 (im FYRW at 20°C and 20 ppt for one week. Water was renewed daily. During that
time, 0.3 mL hemolymph samples were withdrawn from each oyster and diagnosed for P.
marinus following the hemolymph technique (Gauthier & Fisher 1990).
One hundred and eighty oysters, most with light infections, were selected and
randomly assigned to 10 L aquaria in groups of ten. Concentrations of chemical baths
ranged from 100 mg/L to 1 mg/L. Compounds considered non toxic to oysters, namely
amprolium and sulfadimethoxine, were applied as 100 mg/L and 10 mg/L baths.
Cycloheximide and malachite green were applied as 10 mg/L and 1 mg/L baths. Since
oysters did not survive exposure to 10 mg/L or 1 mg/L of malachite green, another
experiment was setup to test that compound at 0.1 mg/L and 0.01 mg/L.
All baths, including untreated controls, were tested in duplicate. Stock solutions of
the chemicals were prepared immediately prior to use by adding 10 mg, 100 mg, or 1000
mg of active ingredients to 10 mL of FYRW in 50 mL centrifuge tubes. Thorough mixing
was accomplished with a vortex blender. All compounds tested in this experiment were
directly dissolved in FYRW. Daily rations of microalgae suspensions were added to each
tube until the volume was raised to 50 mL. Then, the chemical-algae suspension was
mixed as before and added to aquaria every other day for 2 weeks.
Dilution water consisted of 1.0 |lm-FYRW with a salinity of 22 ppt warmed to
20°C. Aeration was provided continuously. Aquaria were covered with sheets of
Plexiglas to avoid possible loss of chemicals at the air interface. Water was changed prior
to addition of chemicals. On days when chemicals were not added to aquaria, oysters were
fed an algae diet as in the previous experiment

After the 2 week treatment, P. marinus diagnosis was performed on a second
hemolymph sample and on a tissue sample taken from each oyster. Tissue samples were
assayed for P. marinus in FTM as previously described. Only tissue diagnosis was
performed on oysters exposed to the lower concentrations of malachite green during the
follow-up experiment
Log transformed prezoosporangia count data was examined by a repeated measure
ANOVA. If the ANOVA indicated significant differences, a Dunnett’s test followed to
identify treatments that differed from controls. In addition, a paired t-test was used to
compare pre-treatment and post-treatment abundance's of P. marinus cells in the
hemolymph samples of oysters from selected treatments. Differences in log transformed
weighted prevalence between treatments were examined by a one way ANOVA. For ail
statistical tests alpha was set at 0.05.

Table 4.

Flow chart of methods for experiment 2. Number of oysters in parenthesis. Treatment groups consisted of 2 replicate aquaria
containing 10 oysters each. Sulfa.= Sulfadimethoxine
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In experiment 3, the effect of a 30 day cycloheximide exposure on P. marinus
infections in oysters was examined. In addition, the subsequent progression of infections
was monitored for 30 days after treatment (Table 5). Two hundred and fifty oysters (66 ±
7 mm mean shell height) were collected from Point of Shoals in the James River in
November 1992, cleaned and 25 oysters were sacrificed for P. marinus diagnosis. A
second diagnostic sample was taken after 10 days of acclimation to 20°C and an ambient
salinity of 20 ppt. The diagnosis was performed on a combined tissue sample as
previously described. Subsequently, the remainder of the oysters were labeled and
randomly assigned to one of four treatments: 30 day exposure to 10 mg/L cycloheximide
bath, 30 day untreated control, 30 day exposure to 10 mg/L cycloheximide followed by 30
days without treatment, and 60 day untreated control. All treatments were tested in
duplicate 25 L aquaria containing 25 oysters each. Chemicals were mixed with algae and
added to aquaria, as in experiment 2, for 30 days. Oysters were fed an algae diet, and
aeration was provided, as in previous experiments. Dilution water consisted of 1.0 pmFYRW with an ambient salinity ranging from 16 to 20 ppt heated to 20°C. Aquaria were
covered as in the previous experiment. Disease prevalence and intensity were determined,
as described before, for all treatment replicates at 30 days and 60 days. The effects of
treatment and time on transformed prevalence and transformed weighted prevalence were
examined by two way ANOVAs.

Statistical Analysis
For statistical analysis of results from in vitro and in vivo experiments, data were
transformed, if necessary, following Gagnon et al. (1989). Prezoosporangia count data
and weighted prevalence data were log (x+1) transformed, and prevalence(%) was arcsin
transformed. Normality was examined by the Kolmogorov-Smimov test, and
homogeneity of variance by the Cochran and Bartlett/Box tests, using SPSS^ software
(SPSS Inc. 1986). Data used for subsequent analysis were normal and homogeneous at a

In experiment 3, the effect of a 30 day cycloheximide exposure on P. marinus
infections in oysters was examined. In addition, the subsequent progression of infections
was monitored for 30 days after treatment (Table 5). Two hundred and fifty oysters (66 ±
7 mm mean shell height) were collected from Point of Shoals in the James River in
November 1992, cleaned and 25 oysters were sacrificed for P. marinus diagnosis. A
second diagnostic sample was taken after 10 days of acclimation to 20°C and an ambient
salinity of 20 ppt. The diagnosis was performed on a combined tissue sample as
previously described. Subsequently, the remainder of the oysters were labeled and
randomly assigned to one of four treatments: 30 day exposure to 10 mg/L cycloheximide
bath, 30 day untreated control, 30 day exposure to 10 mg/L cycloheximide followed by 30
days without treatment, and 60 day untreated control. All treatments were tested in
duplicate 25 L aquaria containing 25 oysters each. Chemicals were mixed with algae and
added to aquaria, as in experiment 2, for 30 days. Oysters were fed an algae diet, and
aeration was provided, as in previous experiments. Dilution water consisted of 1.0 pmFYRW with an ambient salinity ranging from 16 to 20 ppt heated to 20°C. Aquaria were
covered as in the previous experiment. Disease prevalence and intensity were determined,
as described before, for all treatment replicates at 30 days and 60 days. The effects of
treatment and time on transformed prevalence and transformed weighted prevalence were
examined by two way ANOVAs.

Statistical Analysis
For statistical analysis of results from in vitro and in vivo experiments, data were
transformed, if necessary, following Gagnon et al. (1989). Prezoosporangia count data
and weighted prevalence data were log (x+1) transformed, and prevalence(%) was arcsin
transformed. Normality was examined by the Kolmogorov-Smimov test, and
homogeneity of variance by the Cochran and Bartlett/Box tests, using SPSSX software
(SPSS Inc. 1986). Data used for subsequent analysis were normal and homogeneous at a
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confidence level above 90% (Appendices D and E). ANOVA, Dunnett, and t-tests were
performed using SuperAnova software (Gagnon et al. 1989). Only one control group,
either untreated control or solvent control, was included in the statistical analysis depending
on which gave the more conservative results.

Source o f chemicals
Amphotericin-B, cycloheximide, and 5-fluorocytosine were obtained from Sigma
Chemical Company, St. Louis, MO; Amprolium from MSD-AGVET, St. Louis, MO;
cimetidine from SmithKline Beecham Pharmaceuticals, King of Prussia, PA; ketoconazole
from Research Diagnostics Inc., Flanders, NJ; lasalocid, sulfadimethoxine, and potentiated
sulfadimethoxine from Roche Vitamins and Fine Chemicals, Nutley, NJ; lasalocid,
monensin, and arprinocid from Lilly Research Laboratories, Greenfield, IN; and malachite
green from Argent Chemical Laboratories, Redmond, WA.

of 2 replicate aquaria containing 25 oysters each.

Table 5. Flow chart of methods for experiment 3. Number of oysters in parenthesis. Treatment groups consisted
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RESULTS

In vitro experiments
In experiments using infected hemolymph as a source of P. marinus cells, there
was a significant (P = 0.000) effect of exposure to 100 mg/L on prezoosporangia
abundance. Six chemicals, amphotericin-B, cycloheximide, lasalocid, malachite green,
monensin, and sulfadimethoxine, yielded significantly lower (P < 0.05) prezoosporangia
abundance than the untreated control group or the solvent control group (Fig. 1 and
Tables 6 and 7 A). Average prezoosporangia abundance decreased from 387 cells in the
untreated control group to less than 10 cells in the cycloheximide, lasalocid, and
malachite green groups respectively (Table 8 ); and from 413 cells in the untreated
control group to less than 1 cell in the amphotericin-B group (Table 7B).
At 10 mg/L exposure, there was also a significant (P = 0.000) effect of treatment
on prezoosporangia abundance (Fig. 2 and Tables 7A and 9). At this concentration,
amphotericin-B, lasalocid, and malachite green treatments had significantly (P < 0.05)
lower prezoosporangia abundance than the untreated control group. Average
prezoosporangia abundance decreased from 83 cells in the untreated control group to less
than 3 cells in lasalocid and malachite green groups respectively (Table 10) and from 413
cells in the untreated control group to 25 cells in the amphotericin-B group (Table 7B).
At concentrations lower than 10 mg/L, the effect of treatment on prezoosporangia
abundance was not significant (P > 0.05).

Figure I. Mean abundance of prezoosporangia in infected hemolymph samples after
exposure to 100 mg/L chemical treatments. Abbreviations: UC = untreated control, SC =
solvent control, AMP = amprolium, ARP = arprinocid, CYC = cycloheximide, LAS =
lasalocid, MG = malachite green, MON = monensin, PSUL = potentiated
sulfadimethoxine, SUL = sulfadimethoxine. Bars = means of 3 replicate 0.2 mL
hemolymph samples. Error bars = standard errors. * = significantly lower (p < 0.05) than
untreated control.

PREZOOSPORANGIA ABUNDANCE
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Table 6. One way ANOVA and Dunnett tests describing the effect of 100 rag/L chemical
treatments on mean prezoosporangia abundance in infected hemolymph samples.
Significance level = 0.05.

One way analysis of variance
SOURCE

DF

SS

MS

F-VALUE

P-VALUE

Treatment

8

21.080

2.635

26.758

0.000

Residual

18

1.773

0.098

Dunnett’s test for mean < control. Critical difference = 0.661.
COMPARISON

Control vs.

DIFFERENCE

SIGNIFICANCE

Lasalocid

-2.200

significant

Malachite green

-2.200

significant

Cycloheximide

-2.073

significant

Monensin

-1.508

significant

Sulfadimethoxine

-0.724

significant

Amprolium

-0.599

not significant

Arprinocid

-0.228

not significant

P. sulfadimethoxine

-0.031

not significant

Table 7A. One way ANOVA and Dunnett tests describing the effect of amphotericin-B
treatments on mean prezoosporangia abundance in infected hemolymph samples.
Significance level = 0.05.

One way analysis of variance
SOURCE

DF

SS

MS

F-VALUE

P-VALUE

T reatm ent

4

14.081

3.520

158.229

0.000

R esidual

10

0.222

0.022

Dunnett’s test for mean < control. Critical difference = 0.301.

Control vs.

COMPARISON

DIFFERENCE

SIGNIFICANCE

Amphotericin-B (100 mg/L)

-2.427

significant

Amphotericin-B (10 mg/L)

-1.112

significant

Amphotericin-B (1.0 mg/L)

-2.073

not significant

Amphotericin-B (0.1 mg/L)

-1.508

not significant

Table 7B. Mean abundance of prezoosporangia in infected hemolymph samples after
exposure to amphotericin-B treatments. Values indicate average of three replicate counts
per 0.2 mL pooled hemolymph sample. Standard deviation in parenthesis.

PREZOOSPORANGIA ABUNDANCE
TREATMENT

UNTRANSFORMED

TRANSFORMED

Untreated control

413.67 (97.76)

2.61 (0.11)

Solvent control

356.00 (148.01)

2.53 (0.18)

Amphotericin-B (100 mg/L)

0.33 (0.57)

0.10(0.17)

Amphotericin-B (10 mg/L)

25.33 (5.03)

1.41 (0.08)

Amphotericin-B (1.0 mg/L)

323.67(115.63)

2.49(0.16)

Table 8. Mean abundance of prezoosporangia in infected hemolymph samples after
exposure to 100 mg/L treatments. Values indicate average of three replicate counts per
0.2 mL pooled hemolymph sample. Standard deviation in parenthesis.

PREZOOSPORANGIA ABUNDANCE
TREATMENT

UNTRANSFORMED

TRANSFORMED

Untreated control

387.00 (241.63)

2.53 (0.27)

Solvent control

902.33 (1012.18)

2.73 (0.56)

Amprolium

150.00 (166.96)

1.93(0.61)

Arprinocid

231.33 (155.03)

2.30 (0.27)

Cycloheximide

2.00(1.00)

0.46(0.15)

Lasalocid

1.67 (2.08)

0.33 (0.35)

Malachite green

1.67 (2.08)

0.33 (0.35)

Monensin

9.67 (1.53)

1.02 (0.06)

P. sulfadimethoxine

339.33 (147.55)

2.50(0.20)

Sulfadimethoxine

69.33 (37.90)

1.81 (0.22)

Figure 2. Mean abundance of prezoosporangia in infected hemolymph samples after
exposure to 10 mg/L chemical treatments. Bars = means of 3 replicate 0.2 mL
hemolymph samples. Error bars = standard errors. No error bars shown when replicate
samples were equal. * = significantly lower (P < 0.05) than untreated control.
Abbreviations: UC = untreated control, SC = solvent control, AMP = amprolium, CYC
cycloheximide, LAS = lasalocid, MG = malachite green, MON = monensin, SUL =
sulfadimethoxine.

UC

SC

AMP

CYC
LAS
TREATMENT

MG
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SUL
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Table 9. One way ANOVA and Dunnett tests describing the effects of 10 mg/L chemical
treatments on mean prezoosporangia abundance in infected hemolymph samples.
Significance level = 0.05

One way analysis of variance
SOURCE

DF

SS

MS

F-VALUE

P-VALUE

Treatment

6

14.732

2.455

33.233

0.000

Residual

14

1.034

0.074

Dunnett’s test for mean < control
COMPARISON

DIFFERENCE

CRITICAL

SIGNIFICANCE

DIFFERENCE

Control vs.

Malachite green

-1.919

0.562

significant

Lasalocid

-1.442

0.562

significant

Cycloheximide

-0.446

0.562

not significant

Amprolium

-0.381

0.562

not significant

Sulfadimethoxine

0.400

0.562

not significant

Monensin

0.468

0.562

not significant
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Table 10. Mean abundance of prezoosporangia in infected hemolymph samples after
exposure to 10 mg/L, 1 mg/L, 0.1 mg/L and 0.01 mg/L chemical treatments. Values
indicate average of three replicate counts per 0.2 mL pooled sample. Standard deviation
in parenthesis.
TREATMENT_______________________________ PREZOOSPORANGIA ABUNDANCE
10 me/L EXPOSURE

UNTRANSFORMED

TRANSFORMED

Untreated control

83.00 (15.59)

1.92 (0.09)

Solvent control

341.33 (47.71)

2.53 (0.06)

Amprolium

35.67 (15.82)

1.54(0.18)

Cycloheximide

50.00 (42.57)

1.47 (0.67)

Lasalocid

2.00 (0.00)

0.48 (0.00)

Malachite green

0.00 (0.00)

0.00 (0.00)

Monensin

248.00 (63.41)

2.39(0.11)

Sulfadimethoxine

210.00 (40.29)

2.32 (0.08)

Amprolium

138.33 (81.38)

2.10(0.23)

Cycloheximide

100.33 (20.03)

2.00 (0.08)

Lasalocid

393.67 (51.60)

2.59 (0.06)

Malachite green

86.33 (28.94)

1.92 (0.16)

Monensin

297.33 (28.88)

2.47 (0.04)

Sulfadimethoxine

322.67 (48.76)

2.51 (0.06)

Amprolium

130.00 (23.64)

2.11 (0.08)

Cycloheximide

127.67 (21.57)

2.10 (0.08)

Lasalocid

350.00 (209.01)

2.48 (0.31)

Malachite green

101.67 (32.19)

2.00(0.13)

Monensin

270.00 (76.22)

2.42 (0.14)

Sulfadimethoxine

349.00 (106.30)

2.53 (0.14)

Amprolium

180.00(102.81)

2.21 (0.24)

Cycloheximide

126.67 (24.21)

2.10(0.09)

Lasalocid

269.33 (168.36)

2.34 (0.39)

Malachite green

172.33 (97.68)

2.19(0.26)

Monensin

399.00 (68.09)

2.60(0.07)

Sulfadimethoxine

359.33 (105.10)

2.54 (0.14)

1.0 me/L EXPOSURE

0.1 me/L EXPOSURE

0.01 me/L EXPOSURE
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In tests with cultured P. marinus cells, there was a significant (P = 0.000) effect of
treatment on prezoosporangia abundance (Fig. 3 and Table 11). Amphotericin-B and
lasalocid treatments had significantly (P < 0.05) lower prezoosporangia abundance than
the control treatment (Table 11). Average prezoosporangia abundance decreased from
102 cells in the untreated control group to 35 cells in the amphotericin-B group, and from
124 cells in the untreated control group to 2 cells in the lasalocid group (Table 12).
The effect of treatment on size of prezoosporangia was also significant (P =
0.000) (Fig. 4 and Table 13). Again, only cells exposed to amphotericin-B or lasalocid
were significantly (P < 0.05) smaller in diameter than control cells. Mean diameter of
prezoosporangia in the control groups ranged from 7.8 to 10.2 pm. Amphotericin-B
treated cells averaged 6.7 pm, and lasalocid treated cells averaged 3.6 pm (Table 14).
There was also a significant (P = 0.000) effect of treatment on percent cell
viability (Fig. 5 and Table 15). Among all compounds tested, only amphotericin-B,
lasalocid, and monensin significandy (P < 0.05) reduced cell viability when compared to
the control group. Mean viability of cells in control and amphotericin-B groups was 97%
and 79% respectively (Table 16).
For all in vitro experiments, abundance and size of prezoosporangia were greater
in solvent control groups than in untreated control groups. Cell viability was slighdy
lower for solvent control groups than for untreated control groups.

Figure 3. Mean abundance of prezoosporangia per sample using cultured P. marinus
cells after exposure to 100 mg/L chemical treatments. Abbreviations: UC = untreated
control, SC = solvent control, AMB = amphotericin-B, CIM = cimetidine, CYC =
cycloheximide, FLU = 5-flourocytosine, FUM = fumagillin, KET = ketoconazole. Bars
means of 3 replicate counts. Error bars = standard errors. * = significantly lower (p <
0.05) than untreated control.
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Table 11. One way ANOVA and Dunnett tests describing the effect of 100 mg/L
chemical treatments on prezoosporangia abundance in cultured P. marinus samples.
Significance level = 0.05.
One way analysis of variance
SOURCE

DF

SS

MS

F-VALUE

P-VALUE

Treatm ent

6

58012.825

9668.804

6.817

0.000

Residual

56

79423.111

14818.270

Dunnett’s test for mean < control. Critical difference = 0.184.
DIFFERENCE

SIGNIFICANCE

Amphotericin-B

-0.414

significant

Cimetidine

-0.098

not significant

Ketoconazole

-0.046

not significant

Fumagillin

0.097

not significant

Fluorocytosine

0.103

not significant

Cycloheximide

0.142

not significant

COMPARISON

Control vs.

One way ANOVA and Dunnett tests describing the effect of 100 mg/L lasalocid and
monensin treatments on prezoosporangia abundance in cultured P. marinus samples.
Significance level = 0.05.
One way analysis of variance
SOURCE

DF

SS

MS

F-VALUE

P-VALUE

Treatment

3

20.519

6.840

455.367

0.000

Residual

32

0.481

0.015

Dunnett* s test for mean < control. Critical difference = 0.122.
DIFFERENCE

SIGNIFICANCE

Lasalocid

-1.607

significant

Monensin

0.169

not significant

COMPARISON

Control vs.

Table 12. Mean abundance of prezoosporangia in cultured P. marinus samples after
exposure to 100 mg/L chemical treatments. Values indicate mean of three replicate
counts. Standard deviation in parenthesis.

PREZOOSPORANGIA ABUNDANCE
TREATMENT

UNTRANSFORMED

TRANSFORMED

Untreated control

102.11 (46.70)

1.97 (0.21)

Solvent control

194.89 (341.44)

1.99 (0.46)

Amphotericin-B

35.67 (8.34)

1.55 (0.09)

Cimetidine

86.22 (53.77)

1.87 (0.25)

Cycloheximide

131.33 (30.52)

2.11 (0.10)

Fluorocytosine

124.78 (45.42)

2.07 (0.17)

Fumagillin

119.11(30.87)

2.07 (0.12)

Ketoconazole

86.56 (28.97)

1.92 (0.13)

Mean abundance of prezoosporangia in cultured P. marinus samples after exposure to
100 mg/L lasalocid and monensin treatments. Values indicate mean of three replicate
counts. Standard deviation in parenthesis.
PREZOOSPORANGIA ABUNDANCE
TREATMENT

UNTRANSFORMED

TRANSFORMED

Untreated control

124.67 (26.18)

2.09 (0.08)

Solvent control

183.00 (28.22)

2.26 (0.06)

Lasalocid

2.33 (1.50)

0.48 (0.19)

Monensin

205.56 (46.63)

2.30(0.11)

Figure 4. Mean size of prezoosporangia in cultured P. marinus samples after exposure
100 mg/L chemical treatments. Abbreviations: UC = untreated control, SC = solvent
control, AMB = amphotericin-B, CIM = cimetidine, CYC = cycloheximide, FLU = 5fluorocytosine, FUM = fumagillin, KET = ketoconazole. Bars = means of 75
measurements. Error bars = standard errors. * = significantly lower (p < 0.05) than
untreated control.
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Table 13. One way ANOVA and Dunnett tests describing the effects of 100 mg/L
chemical treatments on mean prezoosporangia size in cultured P. marinus samples.
Significance level = 0.05.

One^/a^anal^sm
SOURCE

DF

SS

MS

F-VALUE

P-VALUE

Treatment

6

1.953

0.325

12.643

0.000

Residual

518

13.335

0.026

Dunnett’s test for mean < control. Critical difference = 0.060.
DIFFERENCE

SIGNIFICANCE

Amphotericin-B

-0.107

significant

Ketoconazole

-0.037

not significant

Fumagillin

0.011

not significant

Fluorocytosine

0.023

not significant

Cimetidine

0.056

not significant

Cycloheximide

0.098

not significant

COMPARISON

Control vs.

One way ANOVA and Dunnett tests describing the effects of 100 mg/L lasalocid and
monensin treatment on mean prezoosporangia size in cultured P. marinus samples.
Significance level = 0.05.
One way analysis of variance
SOURCE

DF

SS

MS

F-VALUE

P-VALUE

Treatment

3

2.145

0.715

45.545

0.000

Residual

251

3.941

0.016

Dunnett’s test for mean < control. Critical difference = 0.056.
COMPARISON

Control vs.

DIFFERENCE

SIGNIFICANCE

Lasalocid

-0.279

significant

Monensin

-0.005

not significant
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Table 14. Mean size of prezoosporangia in cultured P. marinus samples after exposure to
100 mg/L treatments. Values indicate mean of 75 measurements Standard deviation in
parenthesis.

PREZOOSPORANGIA DIAMETER (urn)
TREATMENT

UNTRANSFORMED

TRANSFORMED

Untreated control

9.20 (4.25)

0.96 (0.21)

Solvent control

10.20 (4.36)

1.01 (0.21)

Amphotericin-B

6.68 (2.86)

0.85 (0.16)

Cimetidine

10.08 (3.58)

1.02(0.16)

Cycloheximide

11.04(3.92)

1.06(0.13)

Fluorocytosine

9.20(3.32)

0.98 (0.14)

Fumagillin

8.84 (2.87)

0.97 (0.13)

Ketoconazole

8.04 (3.39)

0.93 (0.21)

Mean size of prezoosporangia in cultured P. marinus samples after exposure to 100 mg/L
lasalocid and monensin treatments. Values indicate mean of 75 measurements. Standard
deviation in parenthesis.
PREZOOSPORANGIA DIAMETER (urn)
TREATMENT

UNTRANSFORMED

TRANSFORMED

Untreated control

7.88 (2.74)

0.93(0.12)

Solvent control

8.12 (2.35)

0.95(0.11)

Lasalocid

3.60(1.22)

0.65 (0.10)

Monensin

8.44(9.72)

0.92(0.15)

Figure 5. Mean percent cell viability in cultured P. marinus samples after exposure to
100 mg/L treatments. Abbreviations: UC = untreated control, SC = solvent control, AMB
= amphotericin-B, CIM = cimetidine, CYC = cycloheximide, FLU = 5-fluorocytosine,
FUM = fumagillin, KET = ketoconazole. Bars = means of 2 replicate counts. Error bars =
standard errors. * = significantly lower (p < 0.05) than untreated control.
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Table 15. One way ANOVA and Dunnett tests describing the effects of 100 mg/L
chemical treatments on percent cell viability in cultured P. marinus samples.
Significance level = 0.05.
O ne_w av^ial^sis_ofvariai^
SOURCE

DF

SS

MS

F-VALUE

P-VALUE

T reatm ent

6

0.520

0.087

10.147

0.000

R esidual

21

0.179

0.009

Dunnett’s test for mean < control. Critical difference = 0.160.
DIFFERENCE

SIGNIFICANCE

Amphotericin-B

-0.325

significant

Fumagillin

-0.087

not significant

Cimetidine

0.041

not significant

Fluorocytosine

0.045

not significant

Ketoconazole

0.070

not significant

Cycloheximide

0.107

not significant

COMPARISON

Control vs.

One way ANOVA and Dunnett tests describing the effects of 100 mg/L lasalocid and
monensin treatments on percent cell viability in cultured P. marinus samples.
Significance level = 0.05.
One way analysis of variance
P-VALUE

SOURCE

DF

SS

MS

F-VALUE

Treatment

2

6.580

3.290

1 .7 0 7 x l0 l9 0.000

Residual

9

1.735 x 10-18 1.927 x 10'19

Dunnett* s test for mean < control. Critical difference = 6.768 x 10' *0.
COMPARISON

Control vs.

DIFFERENCE

SIGNIFICANCE

Lasalocid

-1.571

significant

Monensin

-1.571

significant
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Table 16. Mean percent viability in cultured P. marinus samples after exposure to 100
mg/L chemical treatments. Values indicate average of 2 replicates. Standard deviation in
parenthesis.

PERCENT VIABILITY
TREATMENT

UNTRANSFORMED

TRANSFORMED

Untreated control

99.50 (1.00)

1.53 (0.07)

Solvent control

97.12(2.31)

1.42(0.10)

Amphotericin-B

79.20 (5.55)

1.10 (0.70)

Cimetidine

97.84 (2.54)

1.47 (0.12)

Cycloheximide

99.39 (1.22)

1.53 (0.78)

Fluorocytosine

97.98 (2.44)

1.47(0.12)

Fumagillin

94.63 (1.14)

1.34 (0.03)

Ketoconazole

98.77 (1.78)

1.49 (0.09)

Mean percent viability in cultured P. marinus samples after exposure to 100 mg/L
lasalocid and monensin treatments. Values indicate average of 2 replicates. Standard
deviation in parenthesis.
PERCENT VIABILITY
TREATMENT

UNTRANSFORMED

TRANSFORMED

Untreated control

100 (0.00)

1.57 (0.00)

Solvent control

100.00 (0.00)

1.57 (0.00)

Lasalocid

0.00(0.00)

0.00 (0.00)

Monensin

0.00 (0.00)

0.00 (0.00)
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Toxicity experiment
Oysters from the baseline diagnostic sample were all negative for P. marinus. All
solvent control oysters survived 96 hour exposure to 0.1% DMSO. Among the chemicals
tested in this experiment, only lasalocid and monensin were lethal to oysters. The LC50
for lasalocid was 0.51 mg/L as determined by the graphic method, and 0.59 mg/L with a
95% confidence interval ranging from 0.1 to 10 mg/L by the binomial method (Table
17A). Exposure to 1 mg/L and 10 mg/L of monensin for 96 hours resulted in 10 % and 40
% mortality respectively (Table 17B).

In vivo experiments
At the start of experiment 1, more than half the oysters had light infections
(prevalence = 56%, weighted prevalence = 0.76). By the end of the experiment,
prevalence had increased to more than 80% for treatments and controls alike (Table 18).
There was no significant effect of treatment on prevalence or weighted prevalence ? =
0.369, P = 0.632 respectively (Tables 18 and 19). Comparison of solvent challenged
control groups and untreated challenged control groups did not reveal any effect of
solvent on prevalence or weighted prevalence. However, prevalence and weighted
prevalence were lower for challenged controls than for unchallenged controls (Tables 18
and 19).
At the start of experiment 2, most oysters had light infections (<1000 P. marinus
cells per 0.3 mL of hemolymph). Comparison of parasite cell abundance in hemolymph
samples taken before and after treatment and among treated and untreated groups,
revealed that only oysters exposed to cycloheximide had lower infections after treatment
than they had before treatment (Fig. 6 and Table 20). Tissue samples showed an overall
agreement with hemolymph samples, but intensity estimates were generally higher for
tissue samples within each oyster. At the end of the 15 day period, weighted prevalence
was significantly (P < 0.05) lower in oysters exposed to 10 mg/L of cycloheximide than
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in untreated controls. Average weighted prevalence was 2.10 and 3.78 respectively. In
hemolymph samples, there was a significant (P = 0.015) effect of treatment on
prezoosporangia abundance averaged over time. The effect of time alone, however,
averaged over treatment, was not significant (P = 0.867). Nevertheless, the pattern of
change over time was different for different treatments, as indicated by the significant
(P = 0.000) effect of the interaction term (Table 21). In agreement with results from tissue
diagnosis, only oysters exposed to 10 mg/L of cycloheximide had a significantly lower
(P < 0.05) number of prezoosporangia per unit hemolymph than untreated controls.
No oysters survived exposure to 10 mg/L or 1 mg/L of malachite green after 15
days. More than 50% (21 in 40) of the oysters exposed to malachite green were dead after
chemicals were renewed four times. During the follow-up experiment, all oysters
survived exposure to 0.1 mg/L and 0.01 mg/L of malachite green, but no effect on disease
prevalence or infection intensity was detected at those concentrations.
In experiment 3, the first diagnostic sample indicated a 68% prevalence of mostly
light infections (weighted prevalence = 0.92) at the time oysters were collected. Ten days
after acclimation to 20°C and 20 ppt, prevalence had risen to 95% and intensities had
increased (weighted prevalence = 1.85). Following 30 days of exposure to
cycloheximide, infection prevalence and weighted prevalence declined to 67% and 0.71
respectively (Figs. 7 and 8). At that time, oysters exposed to cycloheximide had fewer
and lighter infections than untreated control oysters. The reduction in weighted
prevalence between treated oysters and untreated control oysters after the treatment
period, in this experiment, was similar to that in the previous experiment (i.e., a 1.50
decline as compared to a 1.68 decline respectively). The effects of treatment on
prevalence and weighted prevalence were both significant (P = 0.000 and P = 0.001
respectively) (Tables 22 and 2 3 ). There was no significant (P = 0.235) effect of time on
prevalence (prevalence was already at the maximum at 30 days in controls), but there was
a significant ( P = 0.014) effect of time on weighted prevalence as it increased both in

control and treated oysters after treatment was halted (Fig. 8 and Table 23). The
interaction effects of treatment and time on prevalence and weighted prevalence were not
significant (P = 0.235 and P = 0.912 respectively).
There was no adverse effect of cycloheximide on oyster survival. Among 100
oysters treated, only 8 died as compared to 4 that died among 100 untreated controls.
Even though sublethal effects were not measured, no overall differences in soft tissue
appearance or wet tissue weight between oysters exposed to cycloheximide and untreated
controls were observed.
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Table 17A. Toxicity of lasalocid to oysters

Nominal concentration

Mortality (%)

of exposure (mg/L)
24 hr.

48 hr.

72 hr.

96 hr.

0.00

0

0

0

0

0.01

0

0

0

0

0.10

0

0

0

0

1.00

50

70

70

70

10.00

70

90

100

100

72 hr.

96 hr.

Table 17B. Toxicity of monensin to oysters

Nominal concentration

Mortality (%)

of exposure (mg/L)
24 hr.

48 hr.

0.00
0.01
0.10
1.00

0
0
0
0

0
0
0
0

0
0
0
10

0
0
0
10

10.00

0

0

30

40
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Table 18. In vivo experiment 1. Mean prevalence and one way ANOVA describing the
effect of chemical treatment on prevalence.

Prevalence after exposure of oysters to amprolium, arprinocid, lasalocid, monensin,
potentiated sulfadimethoxine, and sulfadimethoxine. Values indicate means of two
replicates. Standard deviations in parenthesis.
PREVALENCES)
TREATMENT

UNTRANSFORMED

TRANSFORMED

Untreated unchallenged

96 (0.00)

1.37 (0.00)

Untreated challenged

88 (5.66)

1.22(0.09)

Solvent challenged

94 (2.83)

1.33 (0.06)

Amprolium

96 (5.66)

1.43 (0.20)

Arprinocid

94 (2.83)

1.33 (0.06)

Lasalocid

100 (0.00)

1.57 (0.00)

Monensin

80(22.63)

1.15 (0.31)

Potentiated sulfadimethoxine

92 (0.00)

1.28 (0.00)

Sulfadimethoxine

94 (8.45)

1.39 (0.25)

One way ANOVA on transformed prevalence
SOURCE

DF

SS

MS

F-VALUE

P-VALUE

Treatment

6

0.236

0.039

1.292

0.369

Residual

7

0.213

0.030
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Table 19. In vivo experiment 1. Mean weighted prevalence and one way ANOVA
describing the effect of chemical treatment on weighted prevalence.

Weighted prevalence after exposure of oysters to amprolium, arprinocid, lasalocid,
monensin, potentiated sulfadimethoxine, and sulfadimethoxine. Values indicate
means of two replicates. Standard deviations in parenthesis.___________________
WEIGHTED PREVALENCE
TREATMENT

UNTRANSFORMED

TRANSFORMED

Untreated unchallenged

2.80 (0.79)

0.57 (0.09)

Untreated challenged

1.84(0.17)

0.45 (0.03)

Solvent challenged

1.82 (0.24)

0.45 (0.02)

Amprolium

2.80 (0.62)

0.58 (0.07)

Arprinocid

2.22 (0.71)

0.50(0.10)

Lasalocid

2.94 (1.27)

0.58 (0.14)

Monensin

1.92 (0.91)

0.45 (0.14)

Potentiated sulfadimethoxine

1.76 (0.28)

0.44 (0.04)

Sulfadimethoxine

2.76 (1.19)

0.56(0.14)

One way ANOVA on transformed weighted prevalence
SOURCE________

DF

Treatment

6

Residual

7

SS

MS

F-VALUE

P-VALUE

0.048

0.008

0.745

0.632

0.075

0.011

Figure 6. In vivo experiment 2. Mean abundance of prezoosporangia in repeated
hemolymph samples, before and after a 15 day exposure of infected oysters to chemical
treatments. Abbreviations: UC = untreated control, AMP = amprolium, CYC =
cycloheximide, SUL = sulfadimethoxine. Numbers following acronyms indicate
concentration of exposure in mg/L. Note: One sample of the CYC1 group had more than
100,000 cells after treatment and was excluded from this chart Bars = means per 0.3 mL
hemolymph samples averaged over 16-20 oysters. Dark bars indicate pre-treatment
values. Light bars indicate post-treatment values. Error bars = standard errors. * = final
value significantly lower (p < 0.05) than initial value, and overall value significantly
lower (p < 0.05) than untreated control.

PREZOOSPORANGIA ABUNDANCE/0.3 mL HEMOLYMPH

10000 ^

UC

AMP 10 AMP100 CYC1 CYC10 SUL10 SUL100
TREATMENT
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Table 20. In vivo experiment 2. Mean abundance of piezoosporangia in repeated
hemolymph samples before and after exposure of oysters to amprolium, cycloheximide,
and sulfadimethoxine treatment. Values indicate means per 0.3 mL hemolymph samples
averaged over 16-20 oysters. Standard deviation in parenthesis.

PREZOOSPORANGIA ABUNDANCE
UNTRANSFORMED

TRANSFORMED

TREATMENT

INITIAL

FINAL

INITIAL

FINAL

Untreated control

358 (893)

2913 (10630)

1.57 (1.00)

1.75 (1.34)

Amprolium 10

364 (580)

648(1173)

1.66 (1.05)

2.15 (1.04)

Amprolium 100

165(357)

3233 (9323)

1.32 (0.89)

2.38 (1.15)

Cycloheximide 1

788 (1835)

5769(24605)

1.88 (1.02)

1.05 (1.44)

Cycloheximide 10

233 (519)

25(111)

1.38 (0.98)

0.22 (0.61)

Sulfadimethoxine 10

272 (495)

4080 (10096)

1.52 (1.00)

1.78 (1.41)

1440 (3627)

1.62 (0.89)

1.73 (1.25)

Sulfadimethoxine 100 341 (811)
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Table 21. In vivo experiment 2. Repeated measures ANOVA, Dunnett and t-tests
describing the effects of chemical treatments on prezoosporangia abundance in
hemolymph samples. Significance level = 0.05.

RegeatedmeasureANOVA
SOURCE

DF

SS

MS

F-VALUE

P-VALUE

TREATMENT

6

31.442

5.240

2.756

0.015

SUBJECT(GROUP)

123

233.901

1.902

TIME

1

0.015

0.015

0.028

0.867

TIME*TREATMENT

6

34.151

5.692

10.953

0.000

63.918

0.520

TIME*SUBJECT(GROUP) 123

Dunnett’s test for mean < control. Critical difference = 0.735.
COMPARISON

DIFFERENCE

SIGNIFICANCE

Control vs. Cycloheximide 10

-0.861

significant

Cycloheximide 1

-0.201

not significant

Sulfadimethoxine 10

-0.011

not significant

Sulfadimethoxine 100 0.011

not significant

Amprolium 100

0.185

not significant

Amprolium 10

0.240

not significant

Paired t-test for selected treatments. Hypothesized difference < or = 0.
TREATMENT

MEAN

DF

t-VALUE

P-VALUE

DIFFERENCE
Cycloheximide 10

1.167

19

5.045

0.000

Cycloheximide 1

0.777

19

2.944

0.004

60

Figure 7. In vivo experiment 3. Prevalence after a 30 day exposure of oysters to
cycloheximide, and prevalence 30 days after stopping exposure. UC = untreated control
treatment, CYC10 = 10 mg/L cycloheximide treatment. The bar to the left of each group
corresponds to the diagnostic sample (N = 25 oysters) taken immediately prior to the
initiation of the experiment. Other bars indicate average of 2 replicate groups of 25
oysters. Error bars = standard deviation. No error bars shown when replicate samples
were equal.

PREVALENCE (%)

UC

CYC10
TREATMENT

Figure 8. In vivo experiment 3. Weighted prevalence after a 30 day exposure of oysters
to cycloheximide, and weighted prevalence 30 days after stopping exposure.
Abbreviations: UC = untreated control treatment, CYC10 = 10 mg/L cycloheximide
treatment. The bar to the left of each group corresponds to the diagnostic sample (N = 25
oysters) taken immediately prior to the initiation of the experiment Other bars indicate
average of 2 replicate groups of 25 oysters. Error bars indicate standard deviation. No
error bars shown when replicate samples were equal.

Time = 0
Time = 30 days
Time = 60 days

CYC10
TREATMENT
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Table 22. In vivo experiment 3. Mean prevalence and two-way ANOVA describing the
effects of cycloheximide treatment and time on prevalence.

Mean prevalence before and after exposure of oysters to cycloheximide. Values indicate
mean of two replicates. Standard deviation in parenthesis.
TREATMENT

TRANSFORMED PREVALENCE

PREVALENCE (%)

time = 30 days time = 60 days

time = 30 days

time = 60 days

Untreated control

100.00 (0.00)

100.00 (0.00)

1.571 (0.00)

1.571 (0.00)

Cycloheximide 10

72.00 (8.29)

77.00 (2.83)

0.961 (0.11)

1.071 (0.03)

Two way ANOVA on transformed prevalence
SOURCE

DF

SS

MS

F-VALUE

P-VALl

Treatment

1

0.616

0.616

198.694

0.000

Time

1

0.006

0.006

1.951

0.235

Treatment*Time

1

0.006

0.006

1.951

0.235

Residual

4

0.012

0.003
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Table 23. In vivo experiment 3. Weighted prevalence and two-way ANOVA describing
the effects of cycloheximide treatment and time on weighted prevalence.

Mean weighted prevalence before and after exposure of oysters to cycloheximide. Values
indicate mean of two replicates. Standard deviation in parenthesis.___________________
TREATMENT

TRANSFORMED WEIGHTED

WEIGHTED PREVALENCE

PREVALENCE

time = 30 davs time = 60 days

time = 30 days

time = 60 days

Untreated control

2.21 (0.41)

3.42 (0.47)

0.51 (0.06)

0.64(0.05)

Cycloheximide 10

0.71 (0.17)

1.31 (0.20)

0.23 (0.04)

0.36 (0.04)

Two way ANOVA on transformed weighted prevalence
SOURCE____________DF________ SS__________ MS_________ F-VALUE

P-VALUE

Treatment

1

0.153

0.153

71.583

0.001

Time

1

0.037

0.037

17.204

0.014

Treatment*Time

1

2.9 x 10*5

2.9 x 10'5

Residual_____________4

0.009

0.002

0.0141

0.912
___________
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DISCUSSION

In vitro studies
Among the nine compounds tested on P. marinus-iniected hemolymph, six (i.e.,
amphotericin-B, cycloheximide, lasalocid, malachite green, monensin, and
sulfadimethoxine) showed efficacy in inhibiting P. marinus cells from enlarging in FTM.
Malachite green, amphotericin-B, and lasalocid, followed by cycloheximide, were the
most effective compounds. The concentrations of malachite green active against P.
marinus-infected hemolymph (100 mg/L to 10 mg/L) in the present study were higher
than the range of 2 mg/L to 4 mg/L reported for effective concentrations against the
model protozoan Tetrahymena pyriformis (Griffin 1989).
The results for cycloheximide were similar to those obtained by Ray (1966a). In
Ray’s study, exposure of infected oyster tissue to 25 mg/L of cycloheximide for several
weeks completely inhibited parasite enlargement In the present study, exposure of
infected oyster hemolymph to 100 mg/L for 1 day significantly inhibited the number of P.
marinus cells enlarging in FTM, and exposure to 10 mg/L resulted in some inhibition.
Further comparison of results is not possible because Ray used pieces of infected tissues
and described the degree of inhibition only as slight marked, or complete.
Among the eight compounds tested using cultured P. marinus cells, only two (i.e.,
amphotericin-B and lasalocid showed efficacy in inhibiting the number and size of cells
enlarging to prezoosporangia stage. In addition to the above compounds, monensin
reduced cell viability.
Four chemotherapeutants were tested both on P. marinus-infected hemolymph
and cultured P. marinus cells. Three of them, amphotericin-B, lasalocid and monensin,
had similar effects on parasites regardless of their source. Cycloheximide, however, was
effective against parasites from infected hemolymph but not against cultured forms. The
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lack of detectable activity of cycloheximide on cultured parasites may be related to the
presence of nutrients in the culture medium. It is possible that cultured cells eluded the
adverse effects of cycloheximide on growth and viability by relying on amino acids
present in the culture medium (La Peyie et al. 1993). Composition of culture media can
alter not only susceptibility of parasites to chemotherapeutants but also their temperature
tolerance, protein profile, and virulence (Cline et al. 1983, Marciano-Cabral & Toney
1994). Alternatively, effects of cycloheximide on cultured cells may have occurred but
were not detectable by the assay used. An assay based on amino acid incorporation into
cultured cells would be more specific and sensitive for the determination of activity with
cycloheximide than the one used in the present study based on enlargement or viability.
The concentrations of exposure of amphotericin-B active against P. marinus in
the present study, 100 mg/L -1 0 mg/L, are in agreement with results by Ray (1966a). In
Ray's study, P. marinus cells were markedly inhibited after exposure of infected tissues to
50-100 mg/L of amphotericin-B. Exposure of infected tissues to less than 50 mg/L of
amphotericin-B resulted only in slight inhibition. Concentrations in the range of 10 mg/L
to 100 mg/L of amphotericin-B are, however, well beyond the recommended dose of 2.5
mg/L for antifungal treatment of in vitro cultures (Sigma Chemical Co. 1993).
The concentrations of exposure of lasalocid and monensin active against P.
marinus in the present study (100 mg/L to 10 mg/L) were much higher than the range
0.001 mg/L to 0.005 mg/L found active against the coccidian Eimeria tenella by Ryley
and Wilson (1976). A longer exposure duration (4 days in Ryley & Wilson's study as
compared to 1 day in the present study) and possibly a more sensitive endpoint for
activity (clusters indicating growth of specific life stages) may account for some of the
difference.
The mechanism by which chemicals inhibit P. marinus is probably related to the
general mode of chemical action. Amphotericin-B, cycloheximide, lasalocid, and
monensin may be lethal to P. marinus cells. Amphotericin-B is a polyene antifungal
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antibiotic. The mode of action and toxicity of the polyenes have been attributed to their
ability to bind to sterols in cell membranes producing alterations in permeability
(Grayson, 1982). Polyether ionosphorus compounds (including lasalocid and monensin)
are known to disrupt the electrochemical balance of ions, such as Na+ and K+, which are
involved in maintaining the selective permeability of membranes thereby having a
cytocidal effect. It is not known how coccidia are preferentially affected by polyether
ionosphorus compounds, but it has been proposed that the lack of active transport
mechanisms in coccidia may allow for selective activity of these compounds (McDougald
1982). Cycloheximide is a protein synthesis inhibitor highly active against a large
number of yeasts including fungal pathogens (Ennis & Lubin 1964), but a cytostatic
effect is more likely to have occurred in short term exposures. The mode of action of
cycloheximide is by inhibiting protein synthesis in eukaryotic ribosomes. The inhibition
may involve blocking one or more steps in the initiation and elongation of peptide chains
(Deacon 1984, Obrig et al. 1971).
To some extent, anticoccidial agents (particularly lasalocid and monensin)
showed activity against P. marinus as expected based on the proposed affinities of this
parasite to the coccidians. However, the fact that compounds that are usually considered
antifungal agents (amphotericin-B, malachite green and cycloheximide) were also
effective, does not support the conclusion that anticoccidial compounds are necessarily
the most effective ones against P. marinus.
The implications of these results for the phylogenetic affiliation of P. marinus
with fungi and apicomplexan organisms is difficult to assess because the spectrum of
action of chemotherapeutants often ranges beyond a single group of organisms.
Polyether antibiotic anticoccidial compounds such as lasalocid and monensin, for
instance, have shown activity against Gram-positive bacteria, mycobacteria, and fungi
(Grayson 1982). Aryl-methane dyes, such as malachite green, have a broad spectrum of
action against Gram-positive bacteria, fungi (especially oomycetes), and external

protozoan parasites of fish (Alderman 1985). Cycloheximide activity has been reported
mainly in reference to fungi (Whiffen 1948, Grayson 1982), but it is active against
eukaryotes in general (Deacon 1984). Polyene antibiotics such as amphotericin-B
possess broad antifungal activity and some antiprotozoal activity. Activity of
amphotericin-B, however, is mostly restricted to yeasts, fungi, and molds including
Candida spp., Cryptococcus neoformans, Histoplasma capsulatum, and Blastomyces
dermatidis (Merck & Co. 1986).
It should be noted that no adverse effects of DMSO were detected on P. marinus.
To the contrary, it appears that DMSO may have prevented cell deterioration, as
suggested by the higher prezoosporangia abundance in several solvent control groups as
compared to untreated (FYRW) control groups. Control of microbial contamination by
DMSO could account for the increased cell counts in solvent controls. This suggestion is
supported by the indication that DMSO may not only act as a solvent without interfering
with parasite development or host cell integrity, but by the fact that it may also serve to
sterilize in vitro assays (Ryley & Wilson 1976).

Toxicity studies
Among the six anticoccidials tested in the toxicity experiment, only lasalocid and
monensin caused oyster mortality when applied at 10 mg/L or 1 mg/L. Oyster mortality
related to lasalocid and monensin exposure is not entirely surprising since both chemicals
are polyether ionosphorus compounds known for toxic effects associated with their mode
of action (McDougald 1982). It is difficult to compare acute toxicity of anticoccidials by
bath administration in oysters with that by injection or oral administration in terrestrial
organisms. In mice, the 24 h median lethal dose of lasalocid ranges from 64 mg/kg
(intraperitoneal) to 146 mg/kg (oral) (Grayson 1982). In oysters, the 96 h LC 50 for
lasalocid by bath administration was 0.56 mg/L (this study). Assuming one 24 h
exposure of 1 mg/L of lasalocid to 10 oysters weighing an arbitrary average wet weight
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of 5 g per oyster, in a 10 L bath, and assuming that all the available compound was taken
up in equal parts by oysters and no losses occurred, would result in a tissue concentration
of 1 mg of the compound per 5 g wet tissue weight, or a dose equivalent to 200 mg/kg
which is comparable to the acute toxic dose of lasalocid by oral administration for mice
as previously noted. Most likely, however, only some fraction of the compounds was
taken up by oysters and even less was available to the parasites. To better compare acute
toxicity of compounds to aquatic organisms with that of terrestrial organisms, perhaps the
preferred mode of administration of compounds would be by injection. It should also be
noted that there was no oyster mortality associated with exposure to 0.1% DMSO,
suggesting that DMSO can be used as a solvent at that or lower concentrations.
In addition to anticoccidials affecting oyster survival in the toxicity experiment,
malachite green was lethal to oysters in experiment 1 (in vivo). Similar to monensin and
lasalocid, 10 mg/L and 1 mg/L exposures of malachite green resulted in oyster m ortality
while 0.1 mg/L and 0.01 mg/L did not. Even though experiment 1 was not designed to
determine median lethal doses, results suggest that acute toxicity of malachite green to
oysters may be in the range of that for most freshwater invertebrates (0.51 mg/L - 3.45
mg/L) but lower than that for the Asiatic clam Corbicula leana (122 mg/L), as reported
by Bills et al. (1977). Malachite green is a respiratory enzyme poison known to destroy
mitochondria (Alderman 1985). In addition to its destructive action against
mitochondria, malachite green is known to be teratogenic in laboratory animals, and its
use in aquaculture in the US has therefore not been approved by the FDA (Meyer &
Schnick 1989).

In vivo studies
Experiment 1, designed to determine the effect of chemical baths on preventing
infections, had some drawbacks and its results should be interpreted with caution.
Despite the fact that oysters were collected from an area that had traditionally been free

from P. marinus, the Wye River in Maryland, the baseline diagnostic sample showed
56% prevalence of mostly light infections. Therefore, treatment was not strictly
preventive in the sense that some infections were already established prior to exposure of
oysters to chemical baths. This experiment was not repeated because, at the time, no
source of P. marinus- free oysters was known.
Anticoccidial compounds, including lasalocid and monensin that were active in
vitro at concentrations ranging from 10 mg/L to 1 mg/L, were not effective in vivo at 0.1
mg/L. It is possible that exposure of oysters to 0.1 mg/L of lasalocid and monensin for 4
days was not sufficient to deliver therapeutic levels of these compounds to parasites.
Exposure of oysters to lasalocid or monensin at concentrations above 1 mg/L, however,
was lethal to oysters, as indicated in the toxicity experiment. Therefore, for lasalocid and
monensin the difference between a therapeutic dose and a toxic dose in oysters may be, if
existent, between 0.1 and 1 mg/L. Small differences between therapeutic and toxic doses
of lasalocid and monensin were typical in poultry and other animals (McDougald 1982
and 1990).
Oysters (N = 25) challenged with one daily dose of lx 10? P. marinus cells from
minced oyster tissues for two consecutive days did not exhibit increase infections relative
to unchallenged control oysters. Therefore this challenge was not effective. Mantle
cavity injections containing > 5 x 10^ P. marinus cells per oyster resulted in diseaseinduced mortality after 3 weeks (Mackin 1962). Considering that the "injection method"
is more effective in producing P. marinus infections than the "feeding method" (Ray
1954), the dose and duration of the challenge in experiment 1 may have been below that
required to detect an increase in the number infections. Prior studies using the "feeding
method" with P. marinus-infected tissue minces (Ray 1954, Mackin 1962) have not
reported infective doses in terms of cells but in terms of number of infected oysters used
as a source of parasites, usually ranging from 1 -10.
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In poultry, preventive anticoccidial treatment has been preferable to therapeutic
treatment because coccidiosis is not clinically recognizable until tissue damage associated
with second or third generation schizonts and mortality occurs soon after those signs
appear. Initiation of treatment as soon as clinical signs appear is of value because not all
individuals in a group become infected at the same time (McDougald 1982). Similarly,
preventive or early treatment of P. marinus infections may be more effective than
therapeutic treatment of advanced infections.
Among all compounds tested in experiment 2, designed to examine the effect of
chemical baths on established infections, only cycloheximide was effective in controlling
P. marinus infections while not adversely affecting oyster survival. In contrast to what
has been reported for low salinity exposures (Ragone & Burreson 1993), infections did
not merely stop progressing, but regressed significantly after exposure to cycloheximide.
Both hemolymph and tissue samples confirmed reduction of infections, indicating that
the chemical exposure had some parasiticidal effect. Short term medication may arrest
parasite development whereas long term medication may kill the parasite. This
conclusion agrees with results reported for other antiparasitic compounds (McDougald
1982).
Tissue samples generally showed higher infection intensities than hemolymph
samples suggesting perhaps that established infections in the tissues were not as easily
affected by the chemical as parasites circulating in the hemolymph. Alternatively, higher
parasite abundance in the tissues as compared to hemolymph may only be indicative of a
difference in sensitivity of the two assays; the tissue diagnostic assay being more
sensitive than the hemolymph assay, as proposed by Burreson and Ragone-Calvo (1993).
On the basis o f the in vitro efficacy of amphotericin-B, both on hemolymph and cultured
cells, in vivo trials may be conducted in the future. No attempts to test amphotericin-B in
vivo were carried out during the present investigation because the compound was tested
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during the last part of the study. In addition, amphotericin-B is a relatively expensive
compound.
Experiment 3 clearly defined the effect of cycloheximide on prevalence and
weighted prevalence. Prevalence declined from 95% (prior to treatment) to 67% (after
30 days of exposure to cycloheximide) and weighted prevalence declined from 0.92 to
0.71. These results are in general agreement with those reported by Ray (1966b). In
Ray's study, however, prevalence only slightly declined from 95% (prior to treatment) to
80% (after 30 days of exposure to cycloheximide) while weighted prevalence was
drastically reduced from 3.00 to 1.25. Greater sample size in experiment 3 (N = 25) as
compared to Ray's study (N = 10) may provide more confidence to differences detected
in experiment 3. The magnitude of decline in weighted prevalence after treatment was
similar to experiment 2, suggesting that 15 more days of treatment were not enough to
further reduce infections. However, the fact that several light infections in treated oysters
comprised only a few cells may have prevented a greater effect from being detected.
Thirty days after stopping treatment, prevalence rose to 77% and weighted prevalence
increased to 1.31 in the treated group. A similar increase in weighted prevalence
occurred in the untreated control group. The mode of action of cycloheximide, as an
inhibitor of protein synthesis, probably accounts for the temporary regression of
infections during treatment and subsequent recurrence of infections once treatment was
removed. Cells that survive treatment may be metabolically inactive during the treatment
period. Perhaps a better strategy to control P. marinus infections with cycloheximide
would be to treat infected oysters for 1-2 weeks to kill metabolically active parasites,
withdraw treatment for 1 week to allow "dormant" parasites to develop, followed by
another cycloheximide treatment. This schedule could be repeated until infections were
eliminated or greatly reduced.
In agreement with Ray (1966b), experiment 3 showed that exposure of infected
oysters to 10 mg/L of cycloheximide for 30 days resulted in a decrease in infection
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prevalence and intensity. In experiment 3, prevalence declined from 100% (in the
untreated control group) to 67% (in the treated group) and weighted prevalence declined
from 2.21 to 0.71 respectively.
The magnitude of decline in weighted prevalence in experiment 2 was also similar
to the one observed in experiment 3, suggesting that 15 mote days of treatment were not
enough to further reduce infections. However, the fact that several light infections of
treated oysters comprised only a few cells in experiment 3 may have prevented a greater
effect from being detected. The increase in prevalence and weighted prevalence after
treatment stopped in experiment 3 suggests that the parasiticidal effect of cycloheximide
did not persist beyond the exposure period.
In vitro assays have proven to be useful to screen anti-P. marinus compounds, but
in vivo tests are necessary to identify suitable compounds for treatment of oyster diseases.
Not only does a compound need to be active against the parasite but it also needs to be
available to established infections and not harmful to the host. This agrees with
conclusions for testing of antiparasitic compounds in other animals (Lichtfield 1958,
Schnitzer & Hawking 1963, Ryley & Wilson 1976, Grayson 1982). Comparison of in
vitro activity with in vivo efficacy in the present study indicates that even though several
compounds were active in vitro, only cycloheximide was efficacious in vivo. Lasalocid
and monensin, which were also active in vitro, were toxic to oysters in vivo. Difficulties
in correlating in vitro activity with in vivo efficacy are not unusual and limit the utility of
in vitro tests for predicting in vivo efficacy. Compounds that are very active in vitro may
not be active in vivo, and compounds with minimal in vitro activity may be efficacious in
vivo (Ryley & Wilson 1976).
Sources of discrepancies between in vitro and in vivo tests may be attributed in
part to pharmacodymamics and bioavailability of test compounds to parasites in their host
environment. In the present investigation, delivery of compounds via water baths must
have provided enough quantity of lasalocid and monensin to oysters on the basis of the
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recorded toxic effects. Similarly, enough cycloheximide must have reached established
parasites in oysters given the observed decrease of infections after treatment. It was
assumed that delivery of chemicals mixed with algae or delivered at the same time algae
were provided to aquaria would facilitate uptake by oysters. No measurements were
taken, however, to validate this assumption. Availability of chemicals to oysters may in
fact have been altered by factors such as uptake by algae and loss of chemicals to the air
interface.
In solution, polyether antibiotic agents such as lasalocid and monensin assume a
specific configuration with the center negatively charged and the exterior neutral and
hydrophobic (McDougald 1982). The exterior hydrophobicity of polyether compounds
may facilitate their interaction with organic matter including algae. If so, mixing
polyether compounds with algae may be a good way to administer these compounds to
oysters. With micro-encapsulation techniques (Langdon & Bolton 1984) it may be
possible to improve the delivery of lasalocid and monensin to parasites while avoiding
probable toxic effects to oysters. A recently developed liposomal amphotericin-B
formulation has shown superior efficacy in the treatment of leishmaniasis and no toxicity
to humans. A similar approach may be appropriate for use on oysters, even though the
referred liposomal amphotericin-B formulation is too expensive even for use in humans
(Olliaro & Bryceson 1993).
Cycloheximide is known to be toxic to algae (Bower 1989), but whether uptake
by algae would alter the availability of cycloheximide to oysters is open for speculation.
In aquatic organisms, uptake of chemicals may occur directly from the water through
absorptive epithelia or from the food via the digestive tract. Uptake of compounds
adsorbed to food or sediment particles has generally been considered negligible compared
to uptake from water, but studies including those for bivalves have been contradictory
(Langston 1978, Pruell et al. 1986, and Williams 1989)

74
Loss of chemicals to the air interface may have occurred in the present study
considering that a continuous supply of air bubbles was being delivered to aquaria by air
stones. Use of Plexiglas covers, such as the ones used in the present study, can prevent
chemicals form escaping from aquaria into the surrounding space to some extent, but
offer no assurance against losses of chemicals to the air.
Very little is known about the effects of seawater on the activity of anticoccidial
and antifungal compounds because the compounds have usually been used on terrestrial
or freshwater organisms. Malachite green in alkaline waters rapidly transforms to the
carbinol form which has greater liposolubility and may be more easily absorbed by skin
and gills of fish (Alderman 1985). Cycloheximide may lose its activity in seawater (Ray
1966). Therefore, direct measurements of the chemicals in the water and in oyster
tissues would be necessary to determine the availability of the chemicals to oysters and
parasites.
The recently developed P. marinus cell cultures (La Peyre et al. 1993) facilitates
screening of compounds in vitro, but the advantage of using propagated cells may be
offset if, as in the case of cycloheximide, no activity can be detected. Further studies are
needed to compare and refine tests using culture and non-cultured P. marinus cells.
Studies that may follow this line of research, however, should also note that the potential
applications of chemotherapy to P. marinus-infected oysters may be restricted to small
lots of oysters maintained in closed systems. It is debatable whether this approach would
be practical for aquaculture situations where oysters must be grown “in the field.” In
nature, disease pressure from P. marinus is probably continuous during the warm months
and oysters would be re-exposed to infections after treatment. Furthermore, additional
studies concerning the persistence of the chemical in the oyster and in the environment
would be necessary to comply with regulatory requirements.
In summary, cycloheximide baths of at least 10 mg/L renewed every other day for
2 weeks are necessary to reduce P. marinus infections in oysters held at 20 °C and 20 ppL

Continuation of treatment for 2 additional weeks may not result in eradication of the
parasites. Infections may relapse once treatment is stopped and mortalities will most
likely follow. Given its potential to cause harmful effects in humans, the use of
cycloheximide is currently restricted to laboratory applications. All other uses have been
canceled by EPA (Carl Grable, Environmental Protection Agency, pers. comm.).
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Appendix A. Structure of chemotherapeutants used in the present investigation. Note:
Potentiated sulfadimethoxine, a compound based on sulfadimethoxine is not shown.
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Appendix B. List of compounds tested in vitro on oyster hemolymph infected with P.
marinus and on cultured P. marinus cells. * = Compounds tested both on infected
hemolymph and cultured cells.

Compounds tested on infected hemolymph________ Compounds tested on cultured cells

♦Amphotericin-B

*Amphotericin-B

Amprolium

Cimetidine

Arprinocid

Cycloheximide

*Lasalocid
Malachite green
*Monensin

Fumagillin
5-Fluorocytosine
Ketoconazole

Potentiated sulfadimethoxine

*Lasalocid

Sulfadimethoxine

♦Monensin

Appendix C. Summary of in vitro experiments. IH= Experiments in which hemolymph from infected oysters was used. CC
experiments in which P. marinus cultured cells were used.
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Appendix D. Summary of toxicity and in vivo experiments.
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Appendix E. In vitro experiments. Normality (KSZ = Kolmogorov-Smimov statistic). For P > 0.05 accept hypothesis
of normal distribution of data. Homogeneity of variance (Cochran and Bartlett tests). For P > 0.05 accept hypothesis
of homogeneous variance of data *= Bartlett/Box test cannot be performed. Abbreviations: IH = Experiments with infected hemolymph.
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